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Abstract 
We utilized abundant transcriptomic data for the primary classes of brain cancers to study the 
feasibility of separating all of these diseases simultaneously based on molecular data alone. These 
signatures were based on a new method reported herein – Identification of Structured Signatures 
and Classifiers (ISSAC) – that resulted in a brain cancer marker panel of 44 unique genes.  Many 
of these genes have established relevance to the brain cancers examined herein, with others 
having known roles in cancer biology.  Analyses on large-scale data from multiple sources must 
deal with significant challenges associated with heterogeneity between different published 
studies, for it was observed that the variation among individual studies often have a larger effect 
on the transcriptome than did phenotype differences, as is typical.  For this reason, we restricted 
ourselves to studying only cases where we had at least two independent studies performed for 
each phenotype, and also reprocessed all the raw data from the studies using a unified pre-
processing pipeline.  We found that learning signatures across multiple datasets greatly enhanced 
reproducibility and accuracy in predictive performance on truly independent validation sets, even 
when keeping the size of the training set the same.  This was most likely due to the meta-
signature encompassing more of the heterogeneity across different sources and conditions, while 
amplifying signal from the repeated global characteristics of the phenotype.  When molecular 
signatures of brain cancers were constructed from all currently available microarray data, 90% 
phenotype prediction accuracy, or the accuracy of identifying a particular brain cancer from the 
background of all phenotypes, was found.  Looking forward, we discuss our approach in the 
context of the eventual development of organ-specific molecular signatures from peripheral fluids 
such as the blood.  
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Introduction 
 
One important goal in systems medicine is to develop molecular diagnostics that can accurately 
and comprehensively report health and disease states of an organ system [1,2].  The discovery of 
organ-level molecular signatures [3] from global biomolecule expression measurements would 
mark a significant advance toward this goal.  In this regard, genome-wide transcriptomic data are 
readily available, making this a promising source for molecular signatures as well as a good 
means to study the robustness of signatures across different studies.  During the past decade, 
transcriptomics analyses on clinical patient samples have been widely used to uncover cancer-
associated genes [4] and to discover biomarkers for diagnosis, prognosis prediction, or optimal 
therapy selection [5-7].  Recently, RNAs measured in blood have also been used as serum-based 
molecular fingerprints of neurological disease [8].    
  
While many molecular signature studies have focused on identifying differences between case 
(e.g., cancer) and control (e.g., normal), a more clinically relevant and challenging task is the 
multi-category classification problem.  This task pertains especially to identifying signatures for 
molecular screening and monitoring purposes.  Such signatures need to detect and stratify various 
pathological conditions simultaneously; they must therefore be highly specific for a particular 
disease as well as tissue of origin.  The successful identification of more reliable and efficient 
molecular signatures will also be critical for the blood-based, organ-specific diagnostics 
envisioned for the future [9]. 
  
Data-driven, hierarchical approaches to multi-category classification have been investigated 
extensively in machine learning [10,11].  The basic idea of these methods is first to construct a 
classification framework in the form of a hierarchy, so that multi-category classifications can be 
reformulated into a series of binary decision sets (i.e., discriminating one class or group of classes 
from a second class or group of classes).  The next step is to identify binary classifiers for all 
decision points (i.e., nodes and/or edges) of the hierarchy.  This principle can be applied directly 
towards molecular disease classification, wherein all diseases can be organized into a global 
hierarchy of disease sets, where the diseases in each set share common expression patterns.  The 
sets of binary classifiers can further be aggregated into a classifier marker-panel, which can direct 
diagnosis of an unlabeled patient sample down the hierarchical structure towards a particular 
label.  Therefore, the cumulative expression patterns constitute “hierarchically-structured” 
molecular signatures.  
 
A significant drawback to the use of molecular signatures derived from high-throughput—
particularly transcriptomic—data is limited reproducibility and performance accuracy, which is 
often observed across independent studies of what are considered the same disease 
phenotype.  This drawback holds true for both binary and multi-category classification problems.  
The lack of robustness, even for promising results, can be attributed to molecular heterogeneity 
within tumors or other diseased tissue-samples [12,13], complex disease subtypes, various patient 
demographics, and/or other biologically relevant factors.  Another major issue is batch effects, 
which arise from differences or inconsistencies in experimental protocols, data quality, data-
processing techniques, and laboratory conditions and personnel [14].    
 
A promising method to address some of these limitations in robustness is to accumulate and 
combine data from many independent studies into large meta-analyses [15,16].  This integrated 
strategy naturally expands sample sizes across diverse sources and conditions and can therefore 
provide more reliable disease signatures as phenotype-associated signals become stronger relative 
to noise from batch effects and other sources of variance.  
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In this study, we developed a computational approach called Identification of Structured 
Signatures And Classifiers (ISSAC) to identify molecular signatures that simultaneously 
distinguish major cancers of the human brain.  From an integrated dataset of publicly available 
gene expression data, ISSAC provides a global diagnostic hierarchy and corresponding structured 
brain cancer signatures composed of sets of gene-pair classifiers.  The signal in the 
transcriptomics data was sufficient to develop accurate, comprehensive signatures, as long as the 
training set was sampled from the same population as the validation set (i.e., cross validation).  In 
contrast, training on one dataset and testing against an independent set (i.e., an independent study 
measured from another lab) generally failed to reach the same performance due to biological and 
technical sources of dataset variation.  To address this issue, we found that integration of datasets 
from multiple studies enhanced the disease signal sufficiently to mitigate batch effects and greatly 
improve independent validation results for brain cancers.    
 
 
Results/Discussion	  
 
We compiled a multi-study, integrated dataset of brain cancer and normal transcriptomes [17-30] 
(Table 1, Table S1, and Table S2), on which we used our ISSAC algorithm (described below) to 
assemble classifiers into a node (Table 2, Table S3, and Figure 1) and a decision-tree (Table 3, 
Table S4, and Figure 2) marker panel.  Importantly, while developing our algorithm to identify 
molecular signatures of brain cancer, we explored the effects of integrating data from multiple 
studies on classification performance, confirming that our integrated approach does indeed lead to 
more robust phenotype signatures.   
 
Our marker panel consists of 39 total gene pairs and 44 unique genes (46 unique Affymetrix 
microarray probe IDs).  Details on how the gene-pair sets were chosen as classifiers, and how 
they are used for phenotype prediction, can be found in the Materials and Methods section and 
Text S1.  In addition, we discuss how the genes and gene pairs in our marker panel were found to 
have previously confirmed associations with brain cancer.  Overall, we generated a marker panel 
with reasonably high multi-class brain cancer classification accuracy and straightforward 
biological interpretation. 
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Table 1.  Description of all GEO microarray datasets used in this study.  
Phenotype name GEO accession # 
First author 
(publication year) Ref. Sample size 
Affymetrix 
array 
Ependymoma GSE16155 Donson (2009) 17 19 U133 plus2.0 
 GSE21687 Johnson (2010) 18 83 U133 plus2.0 
Glioblastoma 
Multiforme GSE 4412 Freije (2004) 19 59 U133A 
 GSE 4271 Phillips (2006) 20 76 U133A 
 GSE 8692 Liu (2007) 21 6 U133A 
 GSE 9171 Wiedemeyer (2008) 22 13 U133 plus2.0 
 GSE 4290 Sun (2006) 23 77 U133 plus2.0 
Medulloblastoma GSE 10327 Kool (2008) 24 61 U133 plus2.0 
 GSE 12992 Fattet (2009) 25 40 U133 plus2.0 
Meningioma GSE 4780  Scheck (2006) - 62 U133A/U133 plus2.0 
 GSE 9438 Claus (2008) 26 31 U133 plus2.0 
 GSE 16581 Lee (2010) 27 68 U133 plus2.0 
Oligodendroglioma GSE 4412 Freije (2004) 19 11 U133A 
 GSE 4290 Sun (2006) 23 50 U133 plus2.0 
Pilocytic 
Astrocytoma GSE 12907 Wong (2005) 28 21 U133A 
 GSE 5675 Sharma (2007) 29 41 U133 plus2.0 
Normal Brain GSE 3526 Roth (2006) 30 146 U133 plus2.0 
 GSE 7307 Roth (2007) - 57 U133 plus2.0 
Studies that have not been published are denoted as ‘-’.  
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Table 2.  The node marker-panel is a collection of gene-pair classifiers from the nodes of the 
diagnostic hierarchy.  
Node #a Node classesb Gene ic Gene jc kd 
2 EPN  GBM  MDL  MNG  OLG  PA PRPF40A PURA 1 
3 normal PURA PRPF40A 1 
4 EPN  GBM  MDL  OLG  PA NRCAM ISLR 1 
  IDH2 GMDS  
5 MNG ISLR NRCAM 1 
6 EPN  GBM OLG  PA SALL1 PAFAH1B3 2 
  SRI NBEA  
  DDR1e TIA1  
  DDR1e MAB21L1  
  ITPKB PDS5B  
7 MDL PAFAH1B3 SALL1 4 
  NBEA SRI  
  TIA1 DDR1e  
  MAB21L1 DDR1e  
  PDS5B ITPKB  
8 EPN NUP62CL ZNF280A 2 
  GALNS WAS  
  CELSR1 OR10H3  
  TLE4 OLIG2  
9 GBM  OLG  PA ZNF280A NUP62CL 1 
10 GBM  OLG DDX27 KCNMA1 1 
  COX7A2 GNPTAB  
11 PA KCNMA1 DDX27 3 
  GNPTAB NDUFS2  
  APOD PPIA  
  CD59 SNRPB2  
  SEMA3E ADAMTS3  
  CD59 HINT1  
  BAMBI CIAPIN1  
12 GBM FLNA TNKS2 1 
  ITGB3BP RB1CC1  
  DDX27 TRIM8  
13 OLG LARP5 ANXA1 1 
aNode # corresponds to numerical labels in the diagnostic hierarchy shown in Figure 1.  bDisease abbreviation (name): 
EPN (Ependymoma), GBM (Glioblastoma Multiforme), MDL (Medulloblastoma), MNG (Meningioma), OLG 
(Oligodendroglioma), PA (Pilocytic astrocytoma), and normal (Normal brain).  cGene i and gene j are the genes 
expressed higher and lower, respectively, within each gene-pair classification decision rule.  Specifically, the statement 
of “Gene i is expressed higher than Gene j” being true contributes to the expression profile being classified as the 
phenotype(s) of the node.  Gene names, chromosome loci, and Affymetrix microarray platform probe IDs of the 
classifier genes can be found in Table S1.  dThe minimum number of gene-pair classifiers whose decision rule 
outcomes for an expression profile are required to be ‘true (= 1)’ for the profile to be classified as the phenotype(s) of 
the node.  eGenes that share same symbol/name, but correspond to different Affymetrix probe IDs. 
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Figure 1.  Gene-pair sets of the node marker-panel are shown at their corresponding twelve nodes 
in the brain cancer diagnostic hierarchy.  Gene i (left) and Gene j (right) are the genes expressed 
higher and lower within each gene-pair, respectively.  A transcriptome test sample is classified as 
the phenotype(s) of the node if the number of corresponding gene-pairs with a ‘true’ outcome for 
the statement “Gene i is expressed higher than Gene j” is greater than or equal to a threshold k 
defined for that node. 
 
 
Table 3.  The decision-tree marker-panel shows phenotype-specific signatures in the form of 
binary patterns. 
Gene symbolsa Disease binary signaturesb 
Gene i Gene j EPN GBM MDL MNG OLG PA normal 
PRPF40A PURA 1 1 1 1 1 1 0 
NRCAM ISLR 1 1 1 0 1 1 - 
SRI NBEA 1 1 0 - 1 1 - 
NUP62CL OR10H3 1 0 - - 0 0 - 
DDX27 KCNMA1 - 1 - - 1 0 - 
FLNA TNKS2 - 1 - - 0 - - 
aAffymetrix microarray platform probe IDs of the classifier genes are shown in Table S2.  bFor each gene-pair 
comparison (i.e., Is Gene i > Gene j ?), 1 and 0 delineates ‘true’ and ‘false’, respectively, and ‘ – ‘ denotes that the 
outcome is not used for classification. 
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Figure 2.  Gene-pairs of the decision-tree marker-panel are shown at their corresponding edges in 
the brain cancer diagnostic hierarchy.  Gene i and Gene j are the genes expressed higher and 
lower within the gene-pair, respectively.  For a given test sample, the direction of its classification 
down the diagnostic hierarchy is based on the gene-pair classifiers’ true/false outcomes (left/right, 
respectively) for the statement “Gene i is expressed higher than Gene j”. 
 
 
An overview of Identification of Structured Signatures And Classifiers (ISSAC) 
   
Here, we summarize the overall method of ISSAC into three main steps (Figure S1); a detailed 
algorithm and step-by-step guide are presented in the Materials and Methods section and Text S1, 
respectively.  First, ISSAC constructs the framework for brain cancer diagnosis (Figure 3A and 
Figure S2)—a tree-structured hierarchy of all brain phenotypes including ependymoma (EPN), 
glioblastoma multiforme (GBM), medulloblastoma (MDL), meningioma (MNG), 
oligodendroglioma (OLG), pilocytic astrocytoma (PA), and normal brain, built using an 
agglomerative hierarchical clustering algorithm on gene expression training data.  The 
construction of the hierarchy relies on iteratively identifying pairs of phenotype groups based on 
shared features in gene expression.  As shown in Figure 3A, the cumulative set of different 
phenotypes is partitioned into smaller and more homogeneous subsets, thereby decomposing the 
multi-class diagnosis problem into more tractable sub-problems of class prediction. 
  
Second, ISSAC identifies gene-pair classifiers corresponding to the nodes and edges of the 
diagnostic hierarchy (Figures 1 and 2 and Tables 2 and 3).  Both types of classifiers are binary, 
i.e., attempt to distinguish between two sets of phenotypes.  The objective of a node classifier is 
to distinguish the set of phenotypes associated with the node from all other phenotypes.  For 
example, the classifiers of node 6 in Figure 1 and Table 2 can predict the class label of a 
particular transcriptome sample as either glioma (EPN, GBM, OLG, and PA) or non-glioma 
(MNG, MDL, and normal).  In the case of an edge-based, decision-tree classifier, the objective is 
to distinguish the two sets of phenotypes associated with the two child nodes, analogous to rules 
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of an ordinary decision tree.  In the case of the two genes PRPF40A and PURA in Figure 2 and 
Table 3, this classifier determines the label of a sample as either brain cancer or normal 
phenotype.  All classifiers are based on comparing the relative expression values (i.e., ranks) 
between two genes or several pairs of genes within a gene expression profile (Figures 1 and 2 and 
Tables 2 and 3).  The chosen pairs are those that best differentiate between the phenotype sets and 
are based entirely on the reversal of relative expression (Materials and Methods), as previously 
reported [31].  Briefly, the decision rule by Geman et al. is based on two genes (e.g., gene i and 
gene j) for distinguishing between two phenotypes (e.g., class A and class B): If the expression of 
gene i is greater than that of gene j for a given profile, then the phenotype is classified as class A; 
otherwise, class B.  It has been shown that using such simple decision rules with only a small 
number of gene pairs can lead to highly accurate supervised classification of human cancers 
[32,33].  We describe the advantages of using relative expression reversals in Text S2.  In 
addition, we provide a summary of the expression differences between classifier genes i and j in 
Table S5. 
 
Overall, the collection of node classifiers represent a series of coarse-grained to fine-grained 
explanations of the hierarchical groupings and are used in diagnosis to screen for phenotype-
specific expression patterns (described below).  Thus, the hierarchy of binary predictors guides 
classification of an expression profile in a dynamic coarse-to-fine fashion: a classifier is executed 
if and only if all of its ancestor classifiers have been executed and have returned a positive 
response—i.e., predicted the phenotypes in each node.  The cumulative outcome of the node 
classifiers for a given expression profile is the set of its candidate phenotypes, corresponding to 
all the leaves of the hierarchy that were reached and tested positively.  This property means that it 
is possible to traverse multiple paths to multiple leaf nodes, and thus multiple diagnoses may be 
made in this step (though in practice it is usually just one).  For tie-breaking purposes, the 
decision-tree classifiers at the edges of the diagnostic hierarchy are used to reach a unique 
diagnosis. 
  
Finally, ISSAC uses the gene-pair classifiers for class prediction (Figure 3B).  Given a 
transcriptome sample, ISSAC executes the node classifiers in a hierarchical, top-down fashion 
within the disease diagnostic hierarchy to identify the phenotype(s) whose class-specific 
signature(s) is present.  As shown in Figure 3B, transcriptome samples 4-7 all have expression 
signatures of at least one class, i.e., a sample is classified (positive) as at least one terminal node 
(leaf) phenotype.  In contrast, samples 1-3 do not have any class-specific signatures, i.e., samples 
are not positive for any leaf, and are labeled as “Unclassified”.  In case of multiple class 
candidates, i.e., node classifiers for multiple leaves are positive as in samples 6 and 7, the 
ambiguity is resolved by aggregating all the decision-tree classifiers into a classification decision-
tree, thereby leading any expression signature down one unique path toward a single phenotype.  
Once the hierarchy and classifiers were determined, ISSAC distinguished brain cancer 
phenotypes with an accuracy of 90% in ten-fold cross-validation (discussed below).  When the 
individual transcriptomic samples used in the training set were re-examined, ISSAC correctly 
observed all samples with an apparent (resubstitution) accuracy of 94%.  This gives a sense for 
the relatively small degree of over-fitting compared to the cross-validation accuracy estimate.  
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Figure 3.  Comprehensive classification of human brain cancer and normal brain transcriptomes 
using molecular signatures from ISSAC.  A The coarse-to-fine classification process is 
represented by a hierarchically structured groupings of phenotypes.  There is a node classifier for 
each set of phenotypes in the hierarchy, which is designed to respond positively if the sample 
belongs to this set of diseases and negatively otherwise.  Our diagnostic hierarchy has thirteen 
nodes in total, and seven terminal nodes (i.e., leaves).  The node classifiers are executed 
sequentially and adaptively on a given expression profile; a classifier test for a particular node is 
performed if and only if all of its ancestor tests were performed and deemed positive.  The node 
classifiers are used to screen for phenotype-specific signatures.  B Leaves that have positive 
classifier outcomes correspond to the candidate phenotypes of a given expression profile.  If there 
is no candidate phenotype, the expression profile is labeled as ‘Unclassified’.  If only one 
candidate phenotype is identified, the profile is labeled as that phenotype of the respective leaf.  If 
the profile is considered to consist of multiple phenotype signatures, the ambiguity is resolved 
using the decision-tree classifiers based on the same diagnostic hierarchy.  Here, the decision-tree 
classifiers are executed starting from the root of the tree, directing the profile to one of the two 
child nodes sequentially until it completes a full path towards a leaf.  The phenotype label of the 
final destination corresponds to the unique diagnosis. 
 
 
Integrating disparate datasets identifies more robust molecular signatures across 
independent studies 
 
To estimate the robustness of signature accuracy, it is best to test molecular signatures against 
datasets (i.e., patient samples) that are truly independent of the training set (e.g., drawn from a 
different patient population, clinical laboratory, etc.).  To study the effects of training across 
multiple studies, we used glioblastoma (GBM), where we had the highest number of 
transcriptomic datasets for the phenotype.  We trained ISSAC on each of the five transcriptomic 
datasets (i.e., GSE #) of GBM, coupled in each case to all the data from the other brain 
phenotypes.  The full multi-class signatures were completely relearned (every step) with the only 
difference in each case being which single GBM dataset was included in the training stage.  We 
then assessed the accuracy of correctly classifying GBM transcriptomes measured in the four 
held-out datasets from all other possible phenotypes.  We term this evaluation method as “hold-
one-lab-in validation”. 
  
The overall hold-one-lab-in validation performance, or the average of all classification accuracies 
in Figure 3a, was 38%.  This shows that, in general, individual datasets do not consistently yield 
robust molecular signatures.  For example, GBM signatures from GSE8692 (6 samples, ref. 21) 
and GSE9171 (13 samples, ref. 22) led to average accuracies of 22% and 0% for classifying 
independent GBM samples from other studies, respectively.  These significantly low performance 
results are not surprising for these sets given the very small sample numbers.  To an extent, 
relatively larger datasets could indeed yield disease signatures of higher average accuracy.  
However, sample size was not the sole determining factor of signature performance. For example, 
training on GSE4412 (59 samples, ref. 19) gave an average accuracy of 23% (Figure 4a) on the 
remaining GBM samples from the other studies.  As a notable exception, training on GSE4271 
(76 samples, ref. 20) alone resulted in the best overall average accuracy (87%) in correctly 
classifying samples from the four held-out GBM datasets, with individual validation set 
accuracies ranging from 78% to 100% (Table S6).  However, when GSE4290 (77 samples, ref. 
23) was used as the training set, there was over a 30% lower average GBM classification 
accuracy (56%) despite the nearly identical sample size with GSE4271.    
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Figure 4.  Molecular signatures from multi-study, integrated datasets have higher average 
phenotype prediction accuracy and lower performance variance than those from individual 
datasets.  A Hold-one-lab-in validation results for each of the five glioblastoma (GBM) datasets.  
Gray line indicates average accuracy on the four validation sets.  B Leave-one-lab-out validation 
results for each of the five GBM datasets.  Blue and red line indicates average accuracy of GBM 
signatures from leave-one-lab-out (L1LO) validation and hold-one-lab-in (H1LI) validation, 
respectively.  C H1L1 validation to test GBM signatures from GSE4412, GSE4271, and 
GSE4290, while keeping the number of samples in the GBM training set the same.  50 samples 
were randomly selected from each GBM dataset for signature learning.  H1LI validation was 
executed ten times for each of the three GBM datasets.  Error bars indicate standard deviations.  
D L1LO validation to test GBM signatures on GSE4412, GSE4271, and GSE4290 validation 
sets, while 50 total samples were randomly selected from the other four GBM datasets for 
signature learning.  L1LO validation was executed ten times.  E Data from C and D are used to 
show GBM signatures’ accuracies on GSE4412, GSE4271, and GSE4290 validation sets when 
the GBM training data were from individual or combined GBM datasets.  Ψ, Φ, and Ω indicate 
statistical significance relative to GSE4271, GSE4290, and GSE4412, respectively (Tukey’s post-
hoc test, p < 0.01).  F Signal-to-noise ratios (SNRs) from data in E.  SNR was calculated as the 
ratio of average accuracy to standard deviation. 
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We found considerable discrepancy between the minimum and maximum validation set 
accuracies for training sets GSE4412 (0% and 83%, respectively) and GSE4290 (17% and 92%) 
(Table S6).  This indicates that batch effects, as well as potential biological discrepancies between 
populations studied at different sites, can lead to remarkable variation among transcriptomic 
datasets of supposedly the same phenotype.  This “dataset variation” is widespread in large-scale 
expression studies, causing inconsistencies in molecular signature identification and performance 
reproducibility [34].  Large variation within and across transcriptomic datasets of GBM is 
perhaps not surprising, given that GBM is known to have various molecular subtypes 
[35].  Therefore, as mentioned above, molecular signatures from any single dataset need to be 
approached with caution in terms of their generalization.  
  
We next analyzed how the multi-study integration approach affects performance robustness.  One 
of each of the five datasets of GBM was sequentially withheld as the validation set, while all 
remaining gene expression data (including those from all other phenotypes) were used for 
training.  The GBM signature was then evaluated on the held-out validation set.  We term this 
strategy as “leave-one-lab-out validation”.  Classification accuracies using this approach ranged 
from 63% (GBM training set: 155 samples across four datasets; validation set: GSE4271, 76 
samples) to 100% (GBM training set: 225 samples across four datasets; validation set: GSE8692, 
6 samples) (Figure 4b).  The average accuracy of the five leave-one-lab-out validations was 83%, 
which was considerably higher than that obtained from training on individual GBM datasets 
(38%).  We conjecture that this result is due to the underlying variation in the training sets better 
representing the true variation in the population, both by achieving a greater sample size, as well 
as by having the samples come from a broader range of situations. 
  
To evaluate how multi-study dataset integration alone affects performance robustness 
independent of sample size, we performed hold-one-lab-in and leave-one-lab-out validations for 
the studies with the largest number of samples, GSE4412, GSE4271, and GSE4290 (59, 76, and 
77 samples, respectively) while training on the same number of samples for GBM.  More 
specifically, the same steps in the analyses of Figure 4a and Figure 4b were used, while GBM 
signatures were learned from a training set of exactly 50 samples chosen randomly from either an 
individual dataset or across four combined datasets (with the fifth data set left out for validation).  
This process was conducted ten times for each GBM training set.   
  
The average performances of hold-one-lab-in and leave-one-lab-out validations were 47% and 
70%, respectively.  Overall, the results were consistent with our two aforementioned conclusions: 
1) when a molecular signature is learned from an individual dataset, its ability to accurately and 
precisely represent phenotype features across a broad population highly varies depending on the 
particular dataset used for training (Figure 4c and Table S7); and 2) combining datasets 
considerably increased average accuracy (Figure 4d and Table S7).  Thus, dataset integration 
across multiple studies, even without change in sample size, can lead to significant improvements 
in predictive performance. 
 
Lastly, we used the results in Figure 4c and Figure 4d to compare performances of different GBM 
signatures on the same validation set (Figure 4e).  In all cases, signatures from combined datasets 
had, on average, higher classification accuracy than those from any of the individual datasets—
even though the same number of samples was used in the training sets and were tested on a 
validation set independent of the training set.  These results were then used to evaluate the 
precision of a GBM signature’s classification accuracy by calculating its “signal-to-noise ratio 
(SNR)”.  SNR in the accuracy estimate was calculated herein as the ratio of average classification 
accuracy to standard deviation in the accuracy estimate across studies.  We found that, for all 
validation set cases, GBM signatures developed on the basis of multiple datasets had SNRs 
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greater by at least two fold than those from individual data sets.  This clearly shows that learning 
on integrated datasets leads to molecular signatures that have higher and more consistent (i.e. less 
variable) predictive performance (Figure 4f), and motivated our choice in developing the brain 
cancer ISSAC signature to only use cases where we had at least 2 independent studies to learn 
across.  
 
Overall, we have shown that when a broader range of conditions within a particular phenotype is 
presented during the classifier-learning stage, ISSAC can better distinguish the true disease signal 
from noise prior to independent validation.  However, single and/or smaller training sets that were 
used to define the classifiers might not be representative of, or generalizable to, larger populations 
– leading to poor validation results.  Therefore, the utilization of all currently available datasets 
from various sources and conditions may be a promising approach to finding novel diagnostic 
markers, and eventually bringing the successful adaptation of genomic biomarkers into clinical 
practice.  Also, prospective design of studies is generally best when they utilize multiple sites to 
avoid over-fitting to particular contexts. 
 
It is worth mentioning that in some cases, molecular signatures from a single source can have (or 
at least appear to have) superior performance, as demonstrated by the molecular signatures from 
GSE4271.  Specifically, training on a single GSE4271 data set provided higher accuracy (87%, 
Figure 4a) than learning on any of the four sets combined (average 83%, Figure 4b).  Indeed, 
when such surprisingly robust single datasets are identified, they potentiate significant new 
insight into the underlying heterogeneities present in a patient population of a disease phenotype.  
Such data sets can be utilized for follow-up studies, and hence serve as a valuable resource to the 
scientific and medical communities.  It is, however, difficult in practice to predict in advance data 
set robustness, which must be ensured through careful sample collection and data set 
preprocessing techniques.  To help ensure the production of reliable omics-based data sets, we 
recommend the following: 1) Good experimental design, such as clearly defining clinical 
phenotypes of interest; 2) When collecting new experimental data, sufficient sample size must be 
obtained; 3) All aspects of the experimental and analytical procedures must be carefully 
controlled to avoid batch effects; and 4) No confounding from factors unrelated to phenotype(s) 
of interest must occur. 
 
 
Brain cancer marker-panel achieves high classification accuracy in cross-validation 
  
As shown by our leave-one-lab-out validations, learning signatures across multiple datasets 
significantly improved average classification accuracy with concomitant reduction in 
performance variance.  In this regard, the brain cancer marker-panel obtained using all currently 
available microarray data simultaneously (Tables 2 and 3) should represent more robust 
phenotype signatures. 
 
The classification performance of this comprehensive brain cancer marker-panel was evaluated 
by ten-fold cross-validation (Figure S3).  Our marker-panel achieved a 90% average of 
phenotype-specific classification accuracies (Table 4), showing strong promise against a multi-
category, multi-dataset background at the gene expression level.  In addition, we observed higher 
classification accuracy (93%) among the expression profiles for which a unique diagnosis was 
obtained without subsequent disambiguation from the decision-tree (Table S8).  Furthermore, the 
glioblastoma (GBM) classification accuracy previously seen in our leave-one-lab-out analysis 
(83%) is comparable to that seen in cross-validation (85%).  Indeed, that these two accuracies are 
so close suggests that, for GBM, the effects of variability among the datasets from different 
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institutions and time-points have been mostly overcome by integration across multiple training 
studies. 
 
 
Table 4.  Classification performance of brain cancer marker-panel in ten-fold cross-validation. 
Actual phenotype Predicted phenotype (%)a Total 
 EPN GBM MDL MNG OLG PA normal UCb  
EPN 92.2 2.8 0.3 1.7 1.3 0.6 0.2 1.0 102 
GBM 0.7 84.8 0.2 0.5 11.9 0.1 0.3 1.3 231 
MDL 2.2 2.3 91.1 0.8 2.7 0.2 0.0 0.8 101 
MNG 0.1 1.8 0.0 97.5 0.1 0.2 0.0 0.2 161 
OLG 0.5 20.7 0.2 0.0 74.6 2.1 0.0 2.0 61 
PA 1.3 2.3 0.0 0.0 1.3 94.4 0.0 0.8 62 
normal 0.0 0.5 0.0 0.1 0.7 0.0 98.5 0.1 203 
aAccuracies reflect average performance in ten-fold cross-validation conducted ten times.  The main diagonal gives the 
average classification accuracy of each class (bold), and the off-diagonal elements show the erroneous predictions.  
bUC (Unclassified samples). When using the node classifiers, expression profiles that did not exert a signature of any 
phenotype (i.e., did not percolate down to at least one positive terminal node) were rejected from classification.  In this 
case, the Unclassified sample is treated as a misclassification. 
 
  
Four other brain cancers (ependymoma, medulloblastoma, meningioma, and pilocytic 
astrocytoma) have estimated accuracies of at least 91%, suggesting clear differences between 
them and the other phenotypes at the transcriptomic level.  The anatomical region specificity of 
these four cancers may have contributed toward their highly accurate separation, as there are 
regional areas of unique gene expression patterns.  Roth et al. analyzed gene expression of 20 
anatomically distinct regions of the central nervous system [30] and clustered all anatomical sites 
into distinct groups, providing evidence of region-specific expression patterns.  However, results 
from another study analyzing gene expression data from distinct brain regions suggested that 
clustering disparities might also be due to activity of distinct brain cell types, rather than solely on 
region [36,37].  Furthermore, if region specificity played a dominant role in classification, we 
would expect to see a high number of misdiagnoses to occur between the normal brain, which 
was derived from 25 different locations (Text S3), and the six cancers.  Such a trend was not 
observed in Table 4.  Therefore, our predictive results suggest a stronger contribution from 
underlying cell-type specific and disease-intrinsic elements than from region effects alone. 
 
Compared to the cross-validation accuracies of other phenotypes, lower performance was 
observed for GBM and oligodendroglioma (OLG) (85% and 75%, respectively).  This could have 
been mainly a consequence of the limited ability of the marker-panel to correctly differentiate 
these two cancers from each other.  Indeed, the distinction of these two phenotypes from 
transcriptomics seems to be rather difficult in general, and our accuracies here are comparable to 
those reported previously in two-phenotype comparison studies [38,39].  Furthermore, our 
signatures did show an excellent degree of sensitivity (96%) and specificity (97%) for 
distinguishing these two well-progressed gliomas as a set from all other brain phenotypes.  There 
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exist genetic tests and methods that differentiate GBM and OLG well, such as the combined loss 
of chromosome arms 1p and 19q [40], and over-expression of the transcription factor protein 
Olig2 [41], but our goal in this particular study was to evaluate molecular discriminatory power 
as represented in transcriptomes across multiple brain cancers.  
 
 
Marker-panel genes’ association to cancer biology 
 
Several genes in our marker panel are strongly associated with brain cancers, suggesting putative 
relationships to the underlying pathophysiology of their corresponding phenotypes.  One such 
gene is NRCAM (nodes 4 and 5 of Figure 1 and Table 2), which was reported as a marker for 
high-risk neuroblastoma [42] and poor prognostic ependymoma [43].  NRCAM was also found to 
be over-expressed in cell lines derived from pilocytic astrocytomas and glioblastoma multiforme 
tumors [44].  The receptor tyrosine kinase DDR1, a predicted marker gene for PA when 
expressed higher than TIA1 and MAB21L1 (nodes 6 and 7), was found to be over-expressed in 
high-grade gliomas and to promote tumor cell invasion [45].  FLNA was detected in the serum of 
high-grade astrocytoma (grade 3 and GBM) patients [46], and ANXA1, a gene that encodes an 
anti-inflammatory phospholipid binding protein, was implicated in astrocytoma progression [47].  
These reports are consistent with our identification of FLNA and ANXA1 as two classifier genes 
expressed higher in GBM than in oligodendroglioma (nodes 12 and 13).  The basic helix-loop-
helix (bHLH) transcription factor OLIG2 is innately expressed in oligodendrocytes and was 
recently characterized as a key antagonist of p53 function in neural stem cells and malignant 
gliomas [48].  In accordance with lower expression of OLIG2 as an EPN classifier in this study 
(node 8), OLIG2 expression was used as a negative marker to differentiate EPN from other 
gliomas [49].  SEMA3E, one of several classifier genes for PA (node 11), has been reported to 
drive invasiveness of melanoma cells in mice [50].  And finally, mutation to IDH2 (node 4) in 
GBM is well known, with occurrence reported in 80% of secondary glioblastomas [51,52].  That 
the genes in our marker panel have previously confirmed ties to brain cancers raises the question 
of what is the underlying molecular framework surrounding the generation of gene-pair 
classifiers, which would be an interesting direction for future studies.  Among the gene pairs in 
our marker panel, we focus on two pairs (below) in which the genes’ common functional roles or 
relevance to cancer suggest putative relationships to corresponding pathology.  Our discussions 
below point to potential biological relationships underlying the observed gene expression 
reversals, representing hypotheses that require further experimental validation.   
 
One of the classifier gene pairs involved in the differentiation between meningioma and the 
remaining five brain cancers (EPN, GBM, MDL, OLG, PA) are two metabolic enzymes, IDH2 
and GMDS (node 4).  IDH2 converts isocitrate to α-ketoglutarate within the TCA cycle.  This 
reaction produces NADPH, which not only is an essential cofactor for many metabolic reactions, 
but also helps to protect the cell against oxidative damage [53].  Moreover, GMDS aids the 
biosynthesis of GDP-fucose from GDP-mannose in mannose metabolism, in which NADPH is 
produced [54].  That the enzymatic activities of both IDH2 and GMDS participate in the 
conversion between NADP+ and NADPH is interesting, considering the well-known alteration to 
cellular metabolism and deregulated redox balance in cancer [55].  Possible MNG-specific 
mutations in IDH2 and/or GMDS, or changes in the regulatory network that controls the 
expression of these two genes, may affect cellular redox balance and functions of other metabolic 
enzymes.  
 
The TLE4 and OLIG2 gene pair is used to differentiate EPN from GBM, OLG, and PA (node 8).  
TLE4, a human homolog of the Drosophila Groucho protein, represses the Wnt and FGF 
developmental signaling pathways [56-58] by recruiting deacetylases to histones H3 and H4 
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[59].  FGF receptor signaling was reported to control neuronal and glial cell development by 
regulating OLIG2 expression in zebrafish [58].  This connection between these two genes in 
regards to brain cell development could be reflective of the extent of cell-type differentiation (a 
hallmark of cancer), or lack thereof, unique to EPN compared with the other gliomas. 
 
To develop further hypotheses of the functional relationships between the classifiers and 
pathophysiological traits, we looked for statistical enrichment of biological properties (e.g. 
biological processes, chromosome numbers) on an exhaustive list of gene pairs discriminating 
GBM and OLG (Text S4).  Our statistical enrichment of biological processes of gene-set i and 
gene-set j (the union of genes in each gene-pair classifier that are expressed relatively higher and 
lower in GBM, respectively) showed that the genes reflect disease properties.  Specifically, the 
genes that are in gene-set i, or those expressed higher in GBM compared to OLG, were the most 
enriched in the biological process of ‘Immunity and Defense’ (Figure S4); this is in concordance 
with clinical observations showing high degree of inflammation inside malignant tumors (such as 
GBM), as well as the subsequent high number of immune cells.  Our additional reports on the 
statistical enrichment of certain chromosome numbers link our classifiers to known genomic 
aberrations of their respective brain cancers, providing further insight as to why certain genes 
might have been selected as classifiers. 
 
 
Looking ahead: Molecular signatures based on putative blood borne biomolecules offer a 
glimpse into possible molecular diagnostics 
  
The work reported herein has focused on identifying a structured molecular signature that can 
separate major brain cancers simultaneously, as well as on evaluating issues related to 
reproducibility in molecular signatures.  However, our long-term motivation for wanting 
molecular signatures of an organ system is ultimately to find corresponding signatures in the 
blood, where they can be assayed non-invasively.  Blood bathes virtually all organs, which 
secrete proteins and nucleic acids.  Subsets of these secreted biomolecules can potentially 
constitute disease signatures for molecular diagnostics, as measurement technologies mature.  
Moreover, the blood is easily accessible in contrast to biopsies of diseased organs for obtaining 
transcript or protein profiles.  In this regard, the brain represents an organ system where a critical 
need exists to develop non-invasive techniques to monitor its health state through secreted 
proteins. 
  
Previously, organ-specific proteins have been detected in blood; when these proteins changed in 
concentration or chemical structure, the tissue origin of this change was identified [60].  For 
blood-based, organ-specific diagnostics, molecular signatures need to detect and stratify various 
possible cancers and other pathological conditions simultaneously.  In the context of this current 
study, an intriguing question is if training ISSAC on shed or secreted blood borne biomolecule 
measurements identifies molecular signatures that allow us to distinguish health from disease; and 
if diseased, which one and how far has it progressed?  Thus, the approach laid out herein for 
transcriptomics is a foundation for identifying similar signatures from blood proteins as these 
measurements become more abundant. 
  
As proof of concept and to provide candidates for targeted proteomics analysis, we performed the 
above transcriptomic analysis of finding brain cancer signatures using only the genes that are 
annotated to encode extracellular proteins (Materials and Methods).  We trained ISSAC on a total 
of 767 genes that matched this criterion, which led to a new brain cancer marker-panel composed 
of 41 gene-pair classifiers from 71 unique features (Figure S5).  When looking at the case of 
GBM gene-pair classifiers, i.e. 59 node-based genes involved in the detection of either GBM or 
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phenotype groups that include GBM, 11 were previously identified as potential GBM-specific 
serum markers (detected either from GBM cell-line secretome experiments or in human plasma): 
APOD [61], CALU [62], CD163 [63,64], CHI3L1 [65-67], CSF1 [68,69], EGFR [68,70,71], 
IGFBP2 [62,72-75], NID1 [76], PDGFC [77,78], PSG9 [72], and PTN [79].  We provide the 
functional roles of these genes in Table S9.  None of these previous studies performed relative 
abundance comparisons or measured expression ratios, so we are unable to answer at this time 
whether the particular relative expression reversal patterns would be observed in serum.  We were 
not able to find any direct available evidence associating the remaining GBM classifier genes to 
potential serum-based markers.  Nevertheless, we were encouraged that ISSAC was able to verify 
some previously identified potential GBM markers, which provides support for its use towards a 
blood-based test since there is currently no clinically approved GBM-specific, serum-based 
biomarker. 
 
Our marker-panel, composed entirely of genes encoding extracellular products, obtained an 
average classification accuracy of 87% in 10-fold cross-validation (Table S10), which compares 
favorably to the average accuracy we previously achieved using all the genes in the microarray 
(90%).  This suggests that strong signal may possibly persist for phenotype distinction even when 
using only secreted biomolecules from diseased organs.  If indeed there are enough biomolecules 
secreted into the blood at concentrations that can be accurately and consistently detected by e.g., 
targeted mass spectrometry, then there is the very exciting possibility that organ-specific 
pathologies, such as those described above, can be detected from the blood.  This would truly 
make blood a powerful window into health and disease.  
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Materials and Methods 
 
Multi-study dataset of human brain cancer transcriptomes    
 
All transcriptomic data used in our analysis are publicly available at the NCBI Gene Expression 
Omnibus (GEO).  We integrated 921 microarray samples of six brain cancers (ependymoma, 
glioblastoma multiforme, medulloblastoma, meningioma, oligodendroglioma, pilocytic 
astrocytoma) and normal brain across 16 independent studies into a transcriptome multi-study 
dataset.  Importantly, we obtained the raw data (.CEL files) from each of these studies and 
preprocessed them uniformly using identical techniques to greatly reduce extraneous sources of 
technical artifacts (discussed below).  All data manipulation and numerical calculations were 
performed using MATLAB (MathWorks).   
  
To ensure data quality and to help control for systemic bias and batch effects), we used the 
following strict criteria and reasoning for brain phenotype selection: 1) Expression profiles must 
have been conducted on either the Affymetrix Human Genome U133A or U133 Plus 2.0 
microarray platform.  This allowed maximum microarray sample collection without considerable 
reduction in number of overlapping classifier features (i.e., microarray probe-sets).  2) 
Transcriptomic datasets (i.e., GSE #) for each phenotype must have been collected from at least 
two independent sources to help mitigate batch effects.  3) All datasets must have consisted of no 
fewer than 5 microarray samples.  4) All datasets must have originated from primary brain tumor 
or tissue biopsies.  Expression profiles from cell-lines or laser micro-dissections were not used in 
our study to better ensure sample consistency.  5) Raw microarray intensity data (.CEL files) 
must have been available on GEO for consensus preprocessing (described below).  6) Sample 
preparation protocols must have been fully disclosed on GEO.  7) All microarray samples in a 
dataset of a given phenotype were used in order to take into consideration all sources of 
heterogeneity.  That is, no samples were excluded because their gene expression profiles were 
abnormal for their associated phenotypes.  We are aware that this may allow mislabeled samples, 
e.g. samples that were originally misclassified by the histopathologist upon class labeling (Text 
S5), to be used in the classifier-learning stage, and thereby limit the biological “purity” of a 
phenotype in the training set.  This can pose a serious challenge in interpreting misclassified 
samples that actually seem to be a much better match (or even perfect match) to a different 
phenotype, leading to questions of whether a misclassification is due to ISSAC’s limitation in 
distinguishing phenotypes, or whether a re-evaluation of the original tumor biopsy is required.  
Despite these concerns, we concluded this to be the most stringent test.  After an exhaustive 
search on GEO, we identified 921 microarray samples from 16 studies that met the above criteria 
(as of January 2011).  Information on all datasets (e.g., publication sources, Affymetrix platforms, 
GEO dataset IDs, and microarray sample IDs), studies, and GEO microarray sample IDs used in 
our study is available in Table 1, Table S1, and Table S2, respectively.   
  
Raw microarray intensity data (.CEL files) were obtained online from GEO and preprocessed 
uniformly.  More specifically, common probe-sets were found across all transcriptome samples, 
and consensus preprocessing was performed on all the raw microarray image data to build a 
consensus dataset.  This step removes one major non-biological source of variance between 
different studies.  These preprocessed samples were used to build a multi-study integrated dataset 
of human brain cancer and normal brain transcriptomes.  Finally, stringent probe-set filtering was 
used to remove spurious classifier features.  Our consensus preprocessing and probe-set filtering 
methods are explained in further detail below.  Our integrated and uniformly pre-processed 
dataset is available on our group’s webpage (http://price.systemsbiology.net/downloads) as a 
community resource for those who wish to conduct their own analyses. 
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Consensus preprocessing using GCRMA 
 
All gene expression data used in our study were measurements conducted on either the 
Affymetrix Human Genome U133A or U133Plus2.0 oligonucleotide microarrays.  The 
expression level of a target gene on these two platforms is measured by first quantifying the total 
intensity of fluorescently labeled RNA fragments (from patient specimens) that bind to a probe 
set, or the set of complementary 25-mer oligonucleotide probe sequences.  The intensities of all 
probe sets (raw measurements in the form of .CEL files) are then adjusted for background 
variability and normalized across all samples to obtain the target genes’ final expression values. 
 
Raw .CEL data files were downloaded directly from GEO.  Probe set information used in this 
study were based on the latest Affymetrix annotations.  Raw intensity measurements of all 
microarray samples considered in our study were preprocessed collectively (consensus 
preprocessing) using the MATLAB implementation of the microarray preprocessing GCRMA 
[80].  Only the probe sets that map to known genes and exist on both Affymetrix platforms (same 
oligonucleotide sequences) were considered for preprocessing.  The use of individual Affymetrix 
probe sets as classifiers (and not the mean or median of their expression values as demonstrated 
in other microarray-based studies) imposes limitations in the classifiers’ multi-platform 
compliance, as discussed in Text S6 and Text S7. 
 
Probe set filtering using MAS5 calls 	  
Probe sets of Affymetrix microarrays have “perfect match” probes that are exactly 
complementary to the target gene’s mRNA sequence.  They also have “mismatch” probes that 
contain a mismatched nucleotide halfway along the probe sequence, and are used to estimate the 
degree of non-specific binding.  To ensure that a probe set is reliably detected, the measurements 
of the “perfect match” probes must be significantly greater than those of the “mismatch” probes.  
This is usually assessed based on statistical measures.  The MAS5 preprocessing software makes 
expression quality calls based on the nonparametric Wilcoxon signed-rank test.  The “absent” call 
is made when the p-value is greater than 0.06, representing no significant difference between the 
measurements of the “perfect match” and those of the ‘mismatch’ probes [81].  We eliminated 
probes that were determined to be “absent” in all samples of the consensus dataset.  After this 
probe set filtering step, 19,656 probe sets (corresponding to target genes) within each microarray 
sample were kept for further analysis.  
 
All GCRMA preprocessing and MAS5 probe set filtering procedures were conducted separately 
for training and test set samples, i.e., inside each cross-validation or hold-out loop, in order to 
avoid possible cross-talk between the two datasets.  Genes that were excluded based on the 
MAS5 “absent” calls on the training data were also removed from the corresponding test data. 
 
 
Description of ISSAC algorithm 
 
A tree-structured framework for brain cancer diagnostics 	   
Let L denote the set of class labels, in our case the seven brain phenotypes: six cancers and 
normal.  Given an expression profile x, the objective is to determine its true phenotype Y !	  L.   
The main assumption is that there are natural groupings L !  L among the phenotypes.  Thus, 
testing for these groupings can more efficiently utilize the available training data, leading to more 
accurate classification than testing for each phenotype individually.  Based on these attributes, the 
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natural structure to represent L is then a diagnostic hierarchy in the form of a binary hierarchical 
decision tree T.  Each node t !	  T is associated with a set of phenotypes Lt !  L.  The root of T 
contains all the phenotypes and each leaf (terminal node) of T delineates a single phenotype.  
Overall, this representation is nested, in the sense that the set of phenotypes at every non-terminal 
node is the disjoint union of the phenotypes of the two child nodes.  This tree is built from the 
training data by agglomerative hierarchical clustering derived from features of the profiles, as 
discussed below. 
 
Node classifiers are assembled according to the diagnostic hierarchy   
There is a binary classifier ft for every node t !	  T except for the root.  The classifier ft is a 
function of the expression profile x.  Put simply, ft is a collective “test” for phenotypes in Lt 
versus all other phenotypes.  More formally, the classifier returns two possible outcomes: ft (x) = 
1 (i.e., positive) signals that we accept the hypothesis that Y !	  Lt, and ft (x) = 0 (i.e., negative) 
signals that we reject this hypothesis and conclude that Y ! Lt.  In particular, ft is not a test for Lt 
versus the phenotypes in the sibling of t, as would be the case with a standard decision tree.  
Rather, ft looks for traits within a given profile x which characterize all phenotypes in Lt 
simultaneously, such that a positive result signifies that the classifier assumes the true class of x 
belongs to Lt. 
 
Classifier learning begins at the two child nodes of the root, and the classifiers are learned from 
two types of training data.  The positive training data for learning the classifier ft for node t are all 
the expression profiles of the phenotypes in Lt.  The negative training data are all the profiles of 
the phenotypes that are not in Lt.  
 
Being binary, each classifier has two performance metrics: the sensitivity of ft is the probability 
that ft (x) = 1 given x is from the positive training data, and the specificity of ft is the probability 
that ft (x) = 0 given x is from the negative training data.  Due to the coarse-to-fine, hierarchical 
manner in which the classifiers are processed, we required the sensitivity of ft to be as close to 
unity as possible.  This can be accomplished at the expense of specificity by adjusting a threshold, 
as discussed below. The reason for imposing a high sensitivity on each classifier is that if a test 
profile is rejected from belonging to Lt by the classifier when in fact it does belong to Lt, it cannot 
be recovered.  However, the reduced specificity is only local to each node, and the overall 
specificity increases with testing at subsequent nodes.   
 
A coarse-to-fine screening yields candidate phenotypes 
The strategy for processing any given profile x with the diagnostic hierarchy is breadth-first, 
coarse-to-fine.  Starting from the two child nodes of the root, classifiers are executed sequentially 
and adaptively, with ft performed if and only if all its ancestor tests are performed and are 
positive.  More specifically, ft is performed if and only if fs = 1 for every node s ! T between t 
and the root.  As soon as ft = 0 for a non-terminal node t, none of the descendant classifiers in the 
sub-tree rooted at t are performed.  This is because a negative response of ft means that the 
phenotype is unlikely to belong to Lt and the set of phenotypes associated with descendant of t, 
which are necessarily subsets of Lt.  This facilitates pruning whole subsets of phenotypes at once. 
 
The complete coarse-to-fine screening process for x results in a set of detected phenotypes.  We 
denote this set by L(x) !  L.  These are the phenotypes corresponding to a complete chain of 
positive results for all ft from root to leaf.  Equivalently, L(x) is the set of phenotypes that are not 
ruled out by any test performed.  During the diagnostic process, a profile may traverse only one 
path all the way to the terminal node. In this case, L(x) consists of a single phenotype d, and the 
diagnostic process terminates with Y = d as the predicted phenotype.  However, a profile may 
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also traverse multiple branches to the terminal nodes of T, in which case L(x) consists of multiple 
candidate phenotypes (see the discussion on resolving ambiguities below).  Moreover, a profile 
may reach no terminal nodes, in which case L(x) is empty.  When no terminal node is reached, 
the profile is determined to be outside of L, and labeled as ‘Unclassified’.  
 
Resolving ambiguities using a decision-tree approach 
When L(x) consists of multiple phenotypes, it becomes necessary to refine the 
diagnosis.  The ambiguity is resolved by another tree-structured process – an ordinary 
decision tree based on the same diagnostic hierarchy.  For every pair of sibling nodes, e.g., 
Lt = {EPN} and Ls = {GBM,OLG,PA} , we learn a classifier gt,s which tests Y ! Lt versus 
Y ! Ls, just as in an ordinary decision-tree (the process of classifier identification is 
elaborated below).  Starting from the root of the tree, execution of the decision-tree classifiers 
directs a profile to one of two sibling nodes sequentially until it reaches a terminal node.  Unlike 
the process of traversing the hierarchy of node classifiers, a sample that enters the decision tree is 
directed to one and only one leaf node, and hence uniquely labeled. 
 
Classifier design and learning 
Every node classifier is based on expression level comparisons between two genes.  Let G be the 
set of all genes for which we have microarray expression data, and denote the set of all distinct 
pairs of genes by P.  For each gene-pair gi,gj( )  ! P, consider the Boolean feature Zij (x) ! 
0,1{ }  of an expression profile x = xg, g!G{ } .  Zij (x) assumes the value 1 if gene gi  is 
expressed higher than gene gj (i.e., xgi > xgj ) in x, and the value 0 otherwise (i.e., xgi ! xgj ).  
These are the features that have been used in previous work on relative expression reversals [31].  
Each node classifier f is constructed from a small set of gene-pairs P !  P, the binary outcomes 
of Zij  for all i, j( )  ! P, and a constant threshold k.  More specifically, f (x) = 1 if Zijgi ,gj!P( )"  
!  k, and f (x) = 0 otherwise.  The threshold k takes values between 1 and |P|.   
 
There is a classifier of this nature for every node t ! T, except for the root.  The set of gene-pairs 
P = Pt and threshold k = kt depend on the node t.  Hence, for each t, the classifier ft = 1 if at least 
kt of the gene-pair comparisons in Pt are positive Zij =1( ) ; otherwise, ft = 0.  The comparisons 
are chosen such that, for each pair gi,gj( )  in Pt, we expect to see gene gi 	  expressed more than 
gene gj  under the assumption that the phenotype of x belongs to Lt, whereas if the phenotype of 
x does not belong to Lt, we expect to see the reverse.  For every node t, every pair of all gene-pair 
combinations is “scored” by the difference between the probability of the event that Zij  = 1 given 
Y ! Lt and the probability given Y ! Lt.  These probabilities are estimated from the training data, 
and the subset of pairs with the highest scores are chosen.  
 
Since each positive (resp., negative) comparison is viewed as evidence for Y ! Lt (resp., Y ! Lt), 
we can then favor sensitivity over specificity by varying the threshold kt.  That is, by choosing a 
relatively small value for kt relative to the number of comparisons in Pt, we can make it highly 
likely that the classifier responds positively when in fact the sample belongs to the set Lt. We 
show the sets of gene-pairs Pt for each of the twelve nodes in our diagnostic hierarchy in Table 2 
and an illustrative example in Figure 1.  Finally, the decision tree classifiers gt,s are all based on 
comparisons of single gene-pairs at all edges of the diagnostic hierarchy.   
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While multiple gene pairs were used at each decision point in the node-based tree, only a single 
gene pair was used at each decision point in the decision-tree.  This is due to the difference in the 
motivation of building the two trees; the node-based tree was constructed to maximize sensitivity 
and minimize false-positives with as many pairs as necessary, while the decision-tree was 
designed to resolve multiple diagnoses (i.e. ties) which could be done with only one pair.  We 
show the pair of genes for each of the six decision-tree classifiers in Table 3 and Figure 2.  
MATLAB implementations of the ISSAC algorithm and a step-by-step tutorial are available to 
download at http://price.systemsbiology.net/downloads. 	  
Selecting genes that encode extracellular products	  
Using Gene Ontology (GO) annotations, we have identified a list of 767 genes (mapped on 1,085 
total probes) in every transcriptome sample that encode for possible blood-borne proteins.  
Specifically, we selected only the genes whose products are annotated to be in either the 
‘Extracellular Space’ or the ‘Extracellular Region’ cellular locations.  We use this gene set as a 
starting point for targeted blood diagnostics.  All computational steps and analyses in regards to 
molecular signature discovery are identical to those discussed above. 
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Text S1. Step-by-step description of how ISSAC works 
 
 
a. Construction of the disease diagnostic hierarchy 
 
Let L = !!,… ,!!  be the collection of class labels, where !! denotes brain phenotype !.  Using 
expression profiles of the phenotype classes, we first calculate the Top Scoring Pair (TSP) score 
(∆) of all gene-pair combinations between all pair-wise class comparisons.  As previously 
described [1], the TSP score between two classes !! and !!, of two genes, gene ! and gene !, is 
defined as: ∆!,! !! ,!!   =    !!  !  ! !! − !!  !  ! !!  , 
 
where !!  !  ! !!  and !!  !  ! !!  denotes the percentage of samples in !! and !!, respectively, 
whose expression of gene ! is higher than that of gene !.  ∆!"# !! ,!!  denotes the maximum ∆!,! between !! and !! over all gene pairs ! and ! 
 
Let  ! designate an evolving set of groups of labels that starts off as the set of individual class !!,… ,!! .  The brain disease diagnostic hierarchy was constructed by progressively evolving ! 
towards the set of all groupings in the hierarchy using the following steps: 
 
1.  For all pair-wise comparisons of distinct elements in !, we calculate all ∆!"#.  The leaves of 
the class-pair !! and !! with the smallest value of ∆!"# are merged into the first node of the tree, denoted as !!!,!!.  
 
2. ∆!"# of all pair-wise comparisons of the elements in the updated ! are calculated, and the pair 
with the smallest value of  ∆!"# is grouped into the next node of the tree.  Since at this point ! 
contains one non-singleton node and a host of other leaves, the next merging can be either 
between two leaves !! and !!, denoted as !!!,!!, or between a node !!!,!!and a leaf !!, 
denoted as !!!,!!,!!.  Whichever pair with the smallest ∆!"# merges to form a new node in !. 
 
3. This process of finding the minimum ∆!"# for all pair-wise elements in !, and adding the new 
node in !, is iterated until all nodes and leaves are connected to form a tree structure.  All classes 
combine to form the top node !!!,…  ,!! at the top of the diagnostic hierarchy (i.e. root). 
 
b. Identification of the node marker panel 
 
The general idea of the node marker panel discovery method is to find a classifier at every node 
(excluding the root) and leaf of the diagnostic hierarchy.  The node classifiers are based on 
common expression attributes of phenotypes grouped within a particular node; these classifiers 
consist of a set of gene-pair binary decision rules, whose collective ‘true = 1 ’ or ‘false = 0 ’ 
outcomes are to guide classification of a transcriptome test sample towards a brain phenotype.  
The gene-pair classifiers of the node marker panel are identified through the following steps: 
 
1.  Let !! denote all samples included in the training of node t.  These samples correspond to 
phenotypes of either !! ∈ !! or !! ∈ !!!, where !! is the subgrouping of classes at t (we start from 
a child nodes of the root), and !!! represents the set of classes that do not belong to !!.  Using all 
expression profiles in !!, we identify nine disjoint gene pairs (!! ,!!) with the nine highest values 
of ∆!,! between !! and !!!.  This set of gene pairs is denoted as !! = !!,… , !! , where !! is the 
gene-pair with the mth highest ∆!,!.  Here, for any given transcriptome sample, the two genes of !! comprise the following decision rule: If a sample displays the relative expression relation !!! > !!!, then the sample is classified as !!; otherwise, the sample is classified as !!!, where !!! 
and !!! are expression levels of gene ! and gene !, respectively.   
 
When multiple gene pairs achieve the same ∆!,!, the gene pairs are preferentially selected by the 
tie-breaking scheme employed by Tan et al. [1].  Note that since the classification compares !! 
and !!! at each node t, the classifiers of the two child nodes of the root must necessarily be the 
same.  This special case occurs in the child nodes of the root because every class label is 
represented either in the left child or the right child.   
 
2.  For the ! gene pairs in !! with the ! highest TSP scores (! = 1,… ,9), a constant threshold !   ! ≤ !  is found, representing the minimum number of gene pairs required to have ‘true = 1 ’ 
decision rule outcomes in order to have a particular sample classified as !!.  The optimal ! gene 
pairs and threshold ! are found concurrently: !  is the fewest number of gene pairs that yields 
classification sensitivity (percentage of !! samples that are classified as !! ∈ !! correctly) above 
a desired value; ! is optimized to be the threshold that results in the highest overall accuracy, i.e. 
percentage of all samples in !! that are classified correctly. 
 
3.  Using the optimal ! gene pairs and threshold ! found in Step 2, we evaluate all ! gene-pair 
classifiers on every sample of !!, where each classifier’s binary decision rule outcome (on each 
sample) is either ‘true = 1 ’ or ‘false = 0 ’.  The total number of true outcomes for each 
sample is denoted as !.  If ! ≥ !, the sample is labeled ‘positive’ for !! and passes into !!∗ of 
child node t* of t for further classifier training.  However, if ! < !, the sample is labeled 
‘negative’ for !!  and does not pass into !!∗.  In general, most samples of !! ∈ !! passes into !!∗, 
while most samples of !! ∈ !!! do not pass into !!∗.  This updated collection of samples of !!∗ is 
now to be used in Step 4 by the child nodes t*. 
 
4.  We iterate Steps 1-3 on the sibling node, on its child nodes, and so forth.  The classes of !! 
and !!! are dependent upon the current node.  Step 2 is used to find the optimal ! gene pairs and 
threshold !.  Step 3 is used to update !!∗ into smaller and smaller sample subsets.  We iteratively 
train on the samples remaining in each successive !!∗ until gene pairs and thresholds are found 
for all nodes and leaves of the diagnostic hierarchy.   
 	  
c. Identification of the decision-tree marker panel 
 
At each edge of the diagnostic hierarchy, the group of class labels of the parent node is 
partitioned into class labels of the two children.  A classifier is chosen at each edge to direct 
classification to either one of the child nodes.  This classifier is a gene-pair (!! ,!!) that gives ∆!"# !! ,!!  between the classes of the two child nodes, !! and !!.  The decision rule for each 
classifier is: IF !!! > !!!, THEN classify as phenotype !!; ELSE phenotype !!, where !!! and !!! are expression levels of genes !! and !!, respectively.  The collection of gene-pair classifiers 
at all edges of the diagnostic hierarchy is accumulated vertically into a decision-tree marker panel 
(Table 2) to guide classification toward a unique leaf in the diagnostic hierarchy.  The cumulative 
binary outcome for an entire route, from root to leaf, delineates the disease-specific molecular 
signature.   
 
 
d. Diagnosis of transcriptome samples 
 
The node marker panel and the diagnostic hierarchy are used for brain phenotype classification.  
Specifically, the relative expression orderings of the gene-pair classifiers are used to screen for 
disease-specific expression patterns.   
 
Starting at either child node of the root, we use the corresponding set of ! gene pairs and constant 
threshold !.  The value of ! for the transcriptome test sample is compared with !.  If ! ≥ !, the 
sample is ‘positive’ for !! and classification proceeds to both child nodes.  However, if ! < !, 
the sample is ‘negative’ for !!  and classification stops.  We continue this process on the sibling node, on the child nodes, and so forth, unless a sample is deemed ‘negative’ for a particular node.  
A test sample can have one of three diagnostic outcomes:  
 
1.  A single disease class diagnosis, where the sample is ‘positive’ for all the nodes of only one 
entire diagnostic path.  
 
2.  No diagnosis, where the sample is ‘negative’ for at least one node in every path.  Here, the 
sample is rejected from classification, and determined to be none of the brain phenotypes in the 
diagnostic hierarchy. 
 
3.  Multiple diagnoses, where the sample is ‘positive’ for all the nodes of multiple paths.  In this 
case, the classifiers of the decision-tree marker panel are used as a tie-breaker:  All gene-pair 
classifiers’ decision rules are evaluated on the sample, and the resulting binary outcome is 
compared to the binary signatures of the class candidates.  The brain phenotype whose binary 
signature matches that of the test sample is chosen as the unique diagnosis. 
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Text S2. Advantages of using relative expression reversals to build 
classifiers 
 
 
Recently, relative expression orderings (i.e. ranks) among a small number of genes have been 
used for the supervised classification of disease-associated phenotypes [1-3].  The Top-Scoring 
Pair (TSP) classifier, which uses a single gene-pair within an expression profile that exhibits a 
characteristic “relative expression reversal” between two classes of interest, has been shown to be 
a highly accurate and robust strategy in the molecular diagnostics of a variety of human cancers 
[4-6].  The power of this two-gene classifier method extends beyond high classification 
performance; by comparing the ranked expression values of only two genes, this simple 
classification decision rule has remarkably straightforward biological interpretation and 
eliminates the need for parameter estimation and data normalization.  The elimination of the need 
for data normalization across microarrays is advantageous in the clinic, where presumably the 
microarray would not be the measurement platform, because the resulting ISSAC based tests 
require only the genes in the classifier to be measured and do not need all the other genes to 
assure that a normalization is done uniformly.  These are important advantages, since building 
complex decision rules entails the risk of over-fitting, and data preprocessing may introduce 
unwanted bias into the dataset.  For multi-category diagnoses, we extend on the basic idea of the 
TSP classifier into a multi-class, coarse-to-fine search strategy [7,8]. 
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Text S3. Twenty-five anatomical regions of the human brain from 
which normal transcriptome samples were obtained 
 
Roth et al. [1] and Roth et al. (GSE7307, unpublished): Accumbens, amygdala, brain stem, 
caudate, cerebellum, cerebral cortex, entorhinal cortex, frontal lobe, hippocampus, hypothalamus, 
lateral ventricle, medulla, middle temporal gyrus, occipital lobe, optic nerve, posterior cingulate 
cortex, prefrontal cortex, posterior fossa, parietal lobe, putamen, superior frontal gyrus, substantia 
nigra, thalamus, temporal lobe, and visual cortex. 
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Text S4. Global statistical enrichment analysis of gene-pair classifiers  
 
 
Our discussion in the main text on selected marker-panel genes provides some insight into their 
role in disease.  Next, rather than focusing on a limited number of genes (such as only those in 
our marker-panel), we extended our analysis to large sets of gene pairs that distinguish GBM 
from OLG.  We hypothesized that utilizing more complete information would offer more direct 
insight into the basis of the classifiers’ relative expression reversal behavior, by being able to 
associate their global patterns with differences between the pathophysiology underlying the two 
brain cancers. 
 
For any two classes and any given set of gene pairs, the union of the genes that are expressed 
relatively higher (respectively, lower) in each gene pair for Class 1 will be referred to as ‘gene-set 
i’ (resp., ‘gene-set j’).  Thus if there are N gene pairs, then ‘gene-set i’ and ‘gene-set j’ each 
consist of N genes.  For the top 500, 1,000, and 1,500 gene pairs (numbers arbitrarily chosen to 
identify major trends) that best distinguish GBM (Class 1) from OLG (Class 2), we performed an 
enrichment analysis on the biological process ontologies of ‘gene-set i’ (expressed relatively 
higher in GBM than in OLG) and on those of ‘gene-set j’ (expressed relatively lower in GBM 
than in OLG) to find the most consistently enriched category by Z-score. 
 
Information on the biological processes and chromosome numbers of genes is available in the 
PANTHER database [1].  The Z-score is defined as: 
 !! = ! !! − !!!! 1 − !!  
 
where ! is the total number of classifier gene pairs between two classes (e.g. 500, 1000, or 1,500) 
and !! and !! are the proportion of genes characterized by biological category (or chromosome 
number) ! in a given gene set (e.g. gene-set i ) and in the null distribution (i.e. all genes in 
PANTHER), respectively.  
 
Among 18 major biological processes in the PANTHER database, ‘Immunity and Defense’ was 
the most strongly enriched biological process in gene-set i (Figure S4a).  Strong enrichment in 
‘Immunity and Defense’ for the genes expressed relatively higher in GBM reflects the frequently 
observed presence of chronic inflammation in highly malignant cancers [2], such as in GBM [3].  
In a tumor-associated inflammatory micro-environment, immune cells penetrate inside the tumor 
and secrete reactive oxygen species.  This can cause further oxidative DNA damage and 
oncogenic mutations, including amplification of oncogenes or deletion of cell-cycle regulators, 
and thereby facilitate cancer progression, survival, and migration.  Our results show that a 
relatively highly inflamed tumor environment, composed of a deep infiltration of immune cells 
and tumor cells exhibiting functions to embattle such oxidative conditions, is the most 
representative pathophysiological trait that differentiates the tumors of GBM and OLG.  
 
‘Neuronal Activities’ was the most enriched biological process in gene-set j, or the group of 
genes that are expressed lower in GBM compared to OLG (Figure S4b).  This functional category 
includes basic activities of the nerve or neuron behavior, such as synaptic transmission, 
neurotransmitter release, and action potential propagation.  It has been shown that GBM cells 
release glutamate, an amino-acid neurotransmitter [4,5].  Elevated levels of extracellular 
glutamate concentrations is followed by an acute degeneration and death of neurons [4-6], a 
process known as excitotoxicity, and is one of the underlying causes of tumor-associated epileptic 
seizures and neuro-cognitive deficiencies in glioblastoma patients [7].  Therefore, this glutamate 
excitotoxicity in GBM can be the cause of lower normal synaptic transmission and neural 
function relative to OLG, as is suggested by our enrichment results for gene-set j.  Glutamate 
neurotoxicity has also been implicated in other neurodegenerative diseases, including stroke and 
Alzheimer’s disease [8]. 
 
Applying the same enrichment analysis strategy described above for chromosome number, we 
looked for associations between our expression data and gene copy-number alterations frequently 
observed in GBM and OLG.  The genes in gene-set i and gene-set j were the most enriched in 
Chromosome 1 (Figure S4c) and Chromosome 10 (Figure S4d), respectively.  The loss of 
Chromosome 10 is one of the most frequent genetic aberrations in GBM [9,10], causing the 
expression of its genes to be heavily suppressed.  This offers a possible explanation for the over-
representation of Chromosome 10 genes in the gene-set that is expressed relatively less in GBM 
(‘gene-set j’), and thereby higher in OLG.  The deletion of the short-arm of Chromosome 1 is a 
hallmark feature of OLG [11,12], which is what we suspect to have caused the over-
representation of Chromosome 1 genes in the set that is expressed relatively less in OLG (‘gene-
set i’), and thereby higher in GBM.  
 
The results from our global enrichment analysis in biological processes and chromosome 
numbers display the relative differences between the collective properties of the two diseases.  
This offers a holistic view of the major trends that underlie the classifiers’ relative expression 
reversal behavior, which could not have been detected by studying the gene pairs in our marker-
panel alone.  It is worth noting that we did not observe these same enrichment properties in the 
GBM-node or OLG-node classifiers in Table 2.  This reflects a clear limit to the extent of which 
disease properties can be explained by using only the minimal number of classifier genes, since 
those gene pairs were chosen only in the interest of selecting the smallest set with the highest 
predictive accuracy, regardless of biological relevance.   
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Text S5. Whether ISSAC can play a role in identifying misdiagnoses 
 
To know whether a misclassified sample (by ISSAC) had actually been mislabeled by the 
histopathologist (certainly a distinct possibility) would be a difficult task for two reasons: 1) We 
are not able to go back to the “questionable” tumor sample and get a re-evaluation of the clinical 
phenotype as we were not involved in this step; 2) Our markers were trained on all samples 
labeled as a particular phenotype without a sample filtering stage in our pipeline, thereby taking 
into consideration all possible sources of heterogeneity (including potentially mislabeled 
samples).  We did this on purpose to not allow ourselves to reject any variance from the published 
studies, wanting to avoid over-fitting and overly generous accuracy estimations.  These 
conditions make it truly difficult to determine whether a misclassified sample is due to a 
mislabeling by the histopathologist, or a combination of the above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Text S6. Reasoning for selecting only Affymetrix microarray platforms 
and for not using probe-specific offsets 
 
We chose to not include samples from various platforms and technologies (e.g. other Affymetrix 
models, Agilent microarrays, RNA-seq) because of their inherent differences in sample 
preparation steps, hybridization chemistry, probeset/primer length and sequences, data pre-
processing techniques, and so forth – all of which lead to poor correlation of the same features, 
making them not as readily comparable.  This was a choice we made at the beginning of our 
study, as we wanted to study aspects of reproducibility not associated with platform.  We do 
acknowledge that using Affymetrix-based datasets (specifically U133A and U133Plus2.0 array 
chips) is a somewhat restricted case, and that our markers for brain cancers are indeed platform 
specific (which we state in the manuscript).  However, these platforms are still the most widely 
represented in GEO for brain cancers (over 50%).  In addition, we do not anticipate a significant 
change in the main message or impact of our manuscript if we were to apply our technique to a 
smaller sample collection of other platforms and technologies, although, of course, the classifier 
features themselves will likely change.   	  
To the best of our knowledge, there are no confirmed/validated mapping steps (or offsets) that 
one would routinely apply on a subset of probesets for the cross-sample or cross-platform 
purposes.  Furthermore, a simple comparison (such as relative expression comparison used 
throughout this study) is invariant to any monotone pre-processing (in particular any linear 
transformation) of the raw expression values.  However, with an offset, the outcome of the pair 
comparison would no longer be invariant to even scaling.  Thus one would lose robustness.  One 
of the motivations for our method, and one of the reasons relative expression comparison has 
worked in the past, is this invariance.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Text S7. Candidates of brain cancer molecular signatures 
 
We would like to provide a cautionary point that more work is necessary prior to any application 
of our results to a clinical setting.  Indeed, we acknowledge that our markers can only serve as 
classifier candidates at this time.  While we were eager to confirm our markers, we did not have 
brain cancer biopsies at the beginning of our study to validate by qPCR.  Nevertheless, we feel 
that our brain cancer marker candidates, and methods used for their discovery presented herein, 
are valuable resources to those interested in identifying novel molecular signatures from high-
throughput biomolecular data. 
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Figure S1.  The overall method of ISSAC can be summarized into three main steps.  A ISSAC 
constructs the framework for brain cancer diagnosis – a tree-structured hierarchy of all brain 
cancer phenotypes built using an agglomerative hierarchical clustering algorithm on gene 
expression training data.  B Training on gene-expression data from all brain phenotypes, ISSAC 
identifies disjoint, gene-pair classifiers at all nodes (excluding the root) and edges of the 
diagnostic hierarchy, and accumulates them into their respective marker panels.  The chosen pairs 
are the ones that best differentiate between the phenotype sets, and are based entirely on the 
reversal of relative expression.  C ISSAC uses the gene-pair classifiers for class 
prediction.  Briefly, given a gene expression profile, ISSAC executes the node classifiers in a 
hierarchical, top-down fashion within the disease diagnostic hierarchy to identify the 
phenotype(s) whose class-specific signature(s) is present.  In case of multiple class candidates 
(i.e. node classifiers for multiple leaves are positive), the ambiguity is resolved by aggregating all 
the decision-tree classifiers into a classification decision-tree, thereby leading any expression 
signature down one unique path toward a single phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2.  Brain phenotypes are grouped into a global diagnostic hierarchy, which allows an 
intuitive representation of the classification process.  The diagnostic hierarchy is built using a 
data-driven, iterative approach, and is free of manual, ad-hoc construction.  In each iteration, two 
classes, or two groups of classes, with the lowest TSP score (Materials and Methods and Text S1) 
among all pair-wise comparisons, come together to form a node.  This approach optimizes overall 
classification by placing the more challenging decisions further away from the base of the tree 
(i.e. root), thereby ensuring only the minimum misclassifications percolate down the tree.  The 
final form of the brain phenotype diagnostic hierarchy represents a hierarchical structure of 
nested partitions, where the multi-class problem is decomposed into smaller and smaller groups 
using a sequence of diagnostic decision rules. 
 
 
 
 
Figure S3.  Performance evaluation using ten-fold cross-validation.  A Ten-fold cross-validation 
is conducted ten times to obtain the average accuracy.  In every iteration of cross-validation, the 
order of samples within a particular class are randomly permuted before training/test set 
allocations.  B Our marker panel achieved a 90.4% average of phenotype-specific classification 
accuracies, showing strong promise against a multi-category, multi-dataset background at the 
gene expression level.  
 
 
 
 
 
 
 
Figure S4.  Statistical enrichment analysis on PANTHER database biological processes and 
chromosome numbers of the top 500, 1,000, and 1,500 gene-pair classifiers for GBM vs. OLG.  A 
‘Immunity and Defense’ was the most enriched biological process for ‘gene-set i’, reflecting the 
chronic inflammatory conditions inside the GBM tumor.  B ‘Neuronal Activities’ was the most 
enriched biological process for ‘gene-set j’, reflecting decrease in neuronal behavior and possibly 
other brain cell activity inside the GBM tumor.  The genes in ‘gene-set i’ and ‘gene-set j’ were 
the most enriched in C Chromosome 1 and D Chromosome 10, respectively, reflecting the major 
chromosome aberrations of the two brain cancers.  Ψ delineates the most enriched category.  
aBiological process abbreviation (name): AAM (Amino acid metabolism), APT (Apoptosis), CM 
(Carbohydrate metabolism), CA (Cell adhesion), CC (Cell cycle), CPD (Cell proliferation and 
differentiation), CSM (Cell structure and motility), DP (Developmental processes), HMS 
(Homeostatis), IMD (Immunity and defense), IPRT (Intracellular protein transport), MCN 
(Muscle contraction), NA (Neuronal activities), NAM (Nucleic acid metabolism), PMM (Protein 
metabolism and modification), SM (Sulfur metabolism), ST (Signal transduction), and TR 
(Transport).   
 
 
 
 
 
 
Figure S5.  Gene-pair classifiers based on only the genes that encode extracellular products.  
Gene pairs are shown at their corresponding nodes in the brain disease diagnostic hierarchy.  The 
corresponding node-based marker panel consists of 41 classifier pairs and 71 unique classifier 
features.  	  	  	  	  	  	  	  	  
 Table S1.  Phenotype specimen descriptions and main results for all GEO accessions used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
Phenotype
Name
GEO 
accession #
First Author 
(publication year) Phenotype specimen description Main results 
GSE16155 Donson (2009) • Human ependymoma tumor resections
• Genes associated with nonrecurrent ependymoma were predominantly immune function-related
• Histological analysis of a subset of immune function genes revealed that their expression was restricted to tumor-infiltrating subpopulation
• Up-regulation of immune function genes is the predominant ontology associated with a good prognosis in ependymoma 
GSE21687 Johnson (2010) • Human ependymomas comprised of minimum 85% tumour cells
• Identified subgroups of ependymoma, and subgroup-specific gene amplifications and deletions
• Comparative transcriptomics between human tumors and mouse neural stem cells generated mouse models of ependymoma with matching molecular expression patterns
• Developed a novel cross-species genomic approach to match subgroup-specific driver mutations with cellular compartments to model cancer subgroups
GSE4412 Freije (2004) • Diffuse infiltrating gliomas
• Gene expression-based grouping of tumors is a more powerful survival predictor than histologic grade or age
• The expression patterns of 44 genes classify gliomas into previously unrecognized biological and prognostic groups
• Large-scale gene expression analysis and subset analysis of gliomas reveals unrecognized heterogeneity of tumors
GSE4271 Phillips (2006) • Primary high-grade gliomas and matched recurrences
• Novel prognostic subclasses of high-grade astrocytoma closely resemble stages in neurogenesis
• One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival
• Poor prognosis subclasses exhibit either markers of proliferation or of angiogenesis and mesenchyme
• A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis 
gliomas, respectively
GSE8692 Liu (2007) • Primary low/high grade gliomas
• Measured genome-wide mRNA expression levels and miRNA profiles by microarray analysis and RT-PCR, respectively
• Correlation coefficients were determined for all possible mRNA-miRNA pairs
• A subset of high correlated pairs were experimentally validated by overexpressing or suppressing a miRNA and measuring the correlated mRNAs
GSE9171 Wiedemeyer (2008) • Glioblastoma tumors
• A nonheuristic genome topography scan (GTS) algorithm was developed to characterize the patterns of genomic alterations in human glioblastoma (GBM)
• A codeletion pattern found among closely related INK genes in the GBM oncogenome challenges the prevailing single-hit model of RB pathway inactivation 
• Results suggest a feedback regulatory circuit in the astrocytic lineage and demonstrate a bona fide tumor suppressor role for p18INK4C in human GBM 
GSE4290 Sun (2006) • Primary gliomas and nontumor brain samples
• Stem cell factor (SCF) activates brain microvascular endothelial cells in vitro and induces a potent angiogenic response in vivo
• SCF downregulation inhibits tumor-mediated angiogenesis and glioma growth, whereas SCF overexpression is associated with shorter survival in malignant glioma patients
• The SCF/c-Kit pathway plays an important role in tumor- and normal host cell-induced angiogenesis within the brain
• Anti-angiogenic strategies have great potential as a treatment approach for gliomas
GSE10327 Kool (2008) • Primary medulloblastomas and local relapses
• mRNA expression profiling and genomic hybridization arrays show 5 different types of medulloblastoma, each with characteristic pathway activation signatures and associated 
specific genetic defects
• Clinicopathological features significantly different between the 5 subtypes include metastatic disease, age at diagnosis, and histology
GSE12992 Fattet (2009) • Paediatric medulloblastomas
• Immunostaining of !-catenin showed extensive nuclear staining in a subset of samples  
• Expression profiles show strong activation of the Wnt/!-catenin pathway, and complete loss of chromosome 6
• Patients with extensive nuclear staining were significantly older at diagnosis and were in complete remission after a mean follow-up of 75.7 months (range 27.5–121.2 months) 
from diagnosis
• Results confirm previous observations that CTNNB1-mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome
Ependymoma
Glioblastoma
Multiforme
Medulloblastoma
Table S1.  (Continued) Phenotype specimen descriptions and main results for all GEO accessions used in this study. 
 
 
 
 
 
Phenotype
Name
GEO 
accession #
First Author 
(publication year) Phenotype specimen description Main results 
GSE4780 Scheck (2006) • Benign (grade 1) and aggressive (grades 2 and 3) meningiomas • The results of this study have not been publicly disclosed (only data are available)
GSE9438 Claus (2008) • Meningioma specimens without neurofibromatosis type 2, nonrecurrent 
• Progesterone and estrogen hormone receptors (PR and ER, respectively) were measured via immunohistochemistry and compared with gene expression profiling results
• Gene expression seemed more strongly associated with PR status (+/-) than with ER status
• Genes in collagen and extracellular matrix pathways were most differentially expressed by PR status
• PR status may be a clinical marker for genetic subgroups of meningioma
GSE 16581 Lee (2010) • 85 meningioma samples of various grades
• Investigators performed retrospective global genetic and genomic analysis of 85 meningioma samples of various grades
• In addition to chromosome 22q loss, which was detected in the majority of clinical samples, chromosome 6q and 14q loss was significantly more common in recurrent tumors 
and was associated with anaplastic histology
• Five "classes" of meningiomas were detected by gene expression analysis that correlated with copy number alterations, recurrent status, and malignant histology
• Data from this study provide broad genomic information to further stratify meningioma patients into prognostic risk groups
GSE4412 Freije (2004) • Primary high-grade gliomas and matched recurrences
• Novel prognostic subclasses of high-grade astrocytoma are identified and discovered to resemble stages in neurogenesis
• One tumor class displaying neuronal lineage markers shows longer survival, while two tumor classes enriched for neural stem cell markers display equally short survival
• Poor prognosis subclasses exhibit either markers of proliferation or of angiogenesis and mesenchyme
• A robust two-gene prognostic model utilizing PTEN and DLL3 expression suggests that Akt and Notch signaling are hallmarks of poor prognosis versus better prognosis 
gliomas, respectively
GSE4290 Sun (2006) • Primary gliomas and nontumor brain samples
• Stem cell factor (SCF) activates brain microvascular endothelial cells in vitro and induces a potent angiogenic response in vivo
• Downregulation of SCF inhibits tumor-mediated angiogenesis and glioma growth in vivo, whereas overexpression of SCF is associated with shorter survival in patients with 
malignant gliomas
• The SCF/c-Kit pathway plays an important role in tumor- and normal host cell-induced angiogenesis within the brain
• Antiangiogenic strategies have great potential as a treatment approach for gliomas
GSE 12907 Wong (2005) • Juvenile pilocytic astrocytomas (JPAs)
• Genes involved in certain biological processes, including neurogenesis, cell adhesion, and central nervous system development, were significantly deregulated in JPA 
compared to those in normal cerebella
• Two major subgroups of JPA based on unsupervised hierarchical clustering
• JPA without myelin basic protein-positively stained tumor cells may have a higher tendency to progress
GSE 5675 Sharma (2007) • Primary pilocytic astrocytomas (PAs) arising sporadically and in patients with neurofibromatosis type 1 (NF1)
• No expression signature to discriminate clinically aggressive/recurrent tumors from indolent 
• Unique gene expression pattern for PAs arising in patients with NF1
• Gene expression signature stratified PAs by location (supratentorial versus infratentorial)
• Glial tumors may share an intrinsic, lineage-specific molecular signature that reflects the brain region in which their nonmalignant predecessors originated
GSE3526 Roth (2006)
• 20 anatomically distinct sites of the central nervous system (CNS)
• 8 autopsies for each CNS region
• Patient death was due to sudden death
• Principal component analysis and hierarchical clustering results showed that the expression patterns of the 20 CNS sites profiled were significantly different from all non-CNS 
tissues and were also similar to one another, indicating an underlying common expression signature
• The 20 sites could be segregated into discrete groups with underlying similarities in anatomical structure and, in many cases, functional activity
GSE7307 Roth (2007)
• Normal and diseased human tissues representing over 90 distinct 
tissue types
• Patient death was due to sudden death
• The results of this study have not been publicly disclosed (only data are available)
Normal Brain
Oligodendroglioma
Pilocytic
Astrocytoma
Meningioma
Supplementary Table 2.  GEO microarray sample IDs used in this study. 
 
 
Phenotype
Name
Phenotype
Label
GEO Accession
Series # GEO Microarray Sample ID
GSE16155
GSM404936,GSM404937,GSM404938,GSM404939,GSM404940,GS
M404941,GSM404942,GSM404943,GSM404944,GSM404945,GSM4
04946,GSM404947,GSM404948,GSM404949,GSM404950,GSM4049
51,GSM404952,GSM404953,GSM404954
GSE21687
GSM541060,GSM541061,GSM541062,GSM541063,GSM541064,GS
M541065,GSM541066,GSM541067,GSM541068,GSM541069,GSM5
41070,GSM541071,GSM541072,GSM541073,GSM541074,GSM5410
75,GSM541076,GSM541077,GSM541078,GSM541079,GSM541080,
GSM541081,GSM541082,GSM541083,GSM541084,GSM541085,GS
M541086,GSM541087,GSM541088,GSM541089,GSM541090,GSM5
41091,GSM541092,GSM541093,GSM541094,GSM541095,GSM5410
96,GSM541097,GSM541098,GSM541099,GSM541100,GSM541101,
GSM541102,GSM541103,GSM541104,GSM541105,GSM541106,GS
M541107,GSM541108,GSM541109,GSM541110,GSM541111,GSM541
112,GSM541113,GSM541114,GSM541115,GSM541116,GSM541117,
GSM541118,GSM541119,GSM541120,GSM541121,GSM541122,GSM
541123,GSM541124,GSM541125,GSM541126,GSM541127,GSM5411
28,GSM541129,GSM541130,GSM541131,GSM541132,GSM541133,G
SM541134,GSM541135,GSM541136,GSM541137,GSM541138,GSM5
41139,GSM541140,GSM541141,GSM541142
GSE 4412
GSM99432,GSM99434,GSM99436,GSM99438,GSM99440,GSM9944
2,GSM99444,GSM99446,GSM99448,GSM99450,GSM99452,GSM99
454,GSM99456,GSM99462,GSM99464,GSM99466,GSM99470,GSM
99472,GSM99474,GSM99476,GSM99478,GSM99480,GSM99482,GS
M99484,GSM99486,GSM99488,GSM99490,GSM99492,GSM99494,G
SM99524,GSM99526,GSM99528,GSM99530,GSM99532,GSM99534,
GSM99536,GSM99538,GSM99540,GSM99542,GSM99544,GSM9954
6,GSM99548,GSM99550,GSM99552,GSM99554,GSM99556,GSM99
558,GSM99560,GSM99562,GSM99564,GSM99572,GSM99576,GSM
99578,GSM99580,GSM99582,GSM99584,GSM99586,GSM99588,GS
M99590
Glioblastoma GBM
GSE 4271
GSM96950,GSM96951,GSM96952,GSM96953,GSM96954,GSM9695
5,GSM96956,GSM96957,GSM96958,GSM96959,GSM96960,GSM96
961,GSM96962,GSM96963,GSM96964,GSM96965,GSM96966,GSM
96967,GSM96968,GSM96969,GSM96970,GSM96971,GSM96972,GS
M96973,GSM96974,GSM96975,GSM96976,GSM96977,GSM96978,G
SM96979,GSM96980,GSM96981,GSM96982,GSM96983,GSM96984,
GSM96985,GSM96986,GSM96987,GSM96988,GSM96989,GSM9699
0,GSM96991,GSM96992,GSM96993,GSM96994,GSM96995,GSM96
996,GSM96997,GSM96998,GSM96999,GSM97000,GSM97001,GSM
97002,GSM97003,GSM97004,GSM97005,GSM97006,GSM97007,GS
M97008,GSM97009,GSM97010,GSM97011,GSM97014,GSM97018,G
SM97021,GSM97024,GSM97028,GSM97031,GSM97032,GSM97037,
GSM97040,GSM97041,GSM97042,GSM97044,GSM97048,GSM9704
9
Multiforme
GSE 8692 GSM215420,GSM215422,GSM215423,GSM215425,GSM215426,GSM215427
GSE 9171
GSM231695,GSM231696,GSM231697,GSM231698,GSM231699,GS
M231700,GSM231701,GSM231702,GSM231703,GSM231704,GSM2
31705,GSM231706,GSM231707
GSE 4290
GSM97794,GSM97796,GSM97797,GSM97798,GSM97801,GSM9780
6,GSM97808,GSM97813,GSM97814,GSM97818,GSM97819,GSM97
821,GSM97829,GSM97832,GSM97839,GSM97844,GSM97847,GSM
97851,GSM97852,GSM97856,GSM97859,GSM97861,GSM97863,GS
M97869,GSM97870,GSM97871,GSM97877,GSM97882,GSM97885,G
SM97886,GSM97887,GSM97888,GSM97889,GSM97891,GSM97892,
GSM97893,GSM97894,GSM97895,GSM97896,GSM97898,GSM9790
3,GSM97905,GSM97906,GSM97908,GSM97912,GSM97914,GSM97
915,GSM97917,GSM97918,GSM97919,GSM97922,GSM97924,GSM
97926,GSM97930,GSM97931,GSM97935,GSM97936,GSM97938,GS
M97940,GSM97942,GSM97945,GSM97946,GSM97948,GSM97950,
GSM97952,GSM97953,GSM97954,GSM97955,GSM97959,GSM9796
1,GSM97963,GSM97965,GSM97966,GSM97967,GSM97968,GSM97
969,GSM97971
EPNEpendymoma
Supplementary Table 2.  (Continued) GEO microarray sample IDs used in this study. 
 
 
 
 
GSE 10327
GSM260959,GSM260960,GSM260961,GSM260962,GSM260963,GS
M260964,GSM260965,GSM260966,GSM260967,GSM260968,GSM2
60969,GSM260970,GSM260971,GSM260972,GSM260973,GSM2609
74,GSM260975,GSM260976,GSM260977,GSM260978,GSM260979,
GSM260981,GSM260982,GSM260983,GSM260984,GSM260985,GS
M260986,GSM260987,GSM260988,GSM260989,GSM260990,GSM2
60991,GSM260992,GSM260993,GSM260994,GSM260995,GSM2609
96,GSM260997,GSM260998,GSM260999,GSM261000,GSM261001,
GSM261002,GSM261003,GSM261004,GSM261005,GSM261006,GS
M261007,GSM261008,GSM261009,GSM261010,GSM261011,GSM26
1012,GSM261013,GSM261014,GSM261015,GSM261016,GSM26101
7,GSM261018,GSM261019,GSM261020
GSE 12992
GSM324062,GSM324063,GSM324064,GSM324065,GSM324066,GS
M324067,GSM324068,GSM324069,GSM324082,GSM324083,GSM3
24084,GSM324085,GSM324090,GSM324091,GSM324092,GSM3240
93,GSM324104,GSM324111,GSM324112,GSM324113,GSM324115,G
SM324119,GSM324137,GSM324138,GSM324139,GSM324140,GSM
324141,GSM324508,GSM324512,GSM324513,GSM324514,GSM324
515,GSM324516,GSM324517,GSM324526,GSM325233,GSM325278
,GSM325280,GSM325281,GSM325282
GSE 4780 
GSM108014,GSM108015,GSM108016,GSM108017,GSM108018,GS
M107987,GSM107988,GSM107989,GSM107990,GSM107991,GSM1
07992,GSM107993,GSM107994,GSM107995,GSM107996,GSM1079
97,GSM107998,GSM107999,GSM108000,GSM108001,GSM108002,
GSM108003,GSM108004,GSM108005,GSM108006,GSM108007,GS
M108008,GSM108009,GSM108010,GSM108011,GSM108012,GSM10
8013,GSM108019,GSM108020,GSM108021,GSM108022,GSM10802
3,GSM108024,GSM108025,GSM108026,GSM108027,GSM108028,G
SM108029,GSM108030,GSM108031,GSM108032,GSM108033,GSM
108034,GSM108035,GSM108036,GSM108037,GSM108038,GSM108
039,GSM108040,GSM108041,GSM108042,GSM108043,GSM108044
,GSM108045,GSM108046,GSM108047,GSM108048
GSE 9438
GSM239770,GSM239771,GSM239772,GSM239773,GSM239774,GS
M239775,GSM239776,GSM239777,GSM239778,GSM239779,GSM2
39780,GSM239781,GSM239782,GSM239783,GSM239784,GSM2397
85,GSM239786,GSM239787,GSM239788,GSM239789,GSM239790,
GSM239791,GSM239792,GSM239793,GSM239794,GSM239795,GS
M239796,GSM239797,GSM239798,GSM239799,GSM239800
GSE 16581
GSM416798,GSM416799,GSM416800,GSM416801,GSM416802,GS
M416803,GSM416804,GSM416805,GSM416806,GSM416807,GSM4
16808,GSM416809,GSM416810,GSM416811,GSM416812,GSM4168
13,GSM416814,GSM416815,GSM416816,GSM416817,GSM416818,
GSM416819,GSM416820,GSM416821,GSM416822,GSM416823,GS
M416824,GSM416825,GSM416826,GSM416827,GSM416828,GSM4
16829,GSM416830,GSM416831,GSM416832,GSM416833,GSM4168
34,GSM416835,GSM416836,GSM416837,GSM416838,GSM416839,
GSM416840,GSM416841,GSM416842,GSM416843,GSM416844,GS
M416845,GSM416846,GSM416847,GSM416848,GSM416849,GSM4
16850,GSM416851,GSM416852,GSM416853,GSM416854,GSM4168
55,GSM416856,GSM416857,GSM416858,GSM416859,GSM416860,
GSM416861,GSM416862,GSM416863,GSM416864,GSM416865
GSE 4412 GSM99458,GSM99460,GSM99510,GSM99512,GSM99514,GSM99516,GSM99518,GSM99520,GSM99522,GSM99570,GSM99598
GSE 4290
GSM97799,GSM97822,GSM97823,GSM97824,GSM97830,GSM9783
1,GSM97835,GSM97838,GSM97841,GSM97842,GSM97845,GSM97
854,GSM97857,GSM97860,GSM97862,GSM97864,GSM97865,GSM
97866,GSM97867,GSM97868,GSM97872,GSM97873,GSM97874,GS
M97875,GSM97876,GSM97880,GSM97881,GSM97883,GSM97884,G
SM97897,GSM97900,GSM97901,GSM97902,GSM97904,GSM97907,
GSM97909,GSM97911,GSM97923,GSM97925,GSM97928,GSM9792
9,GSM97933,GSM97934,GSM97944,GSM97947,GSM97949,GSM97
956,GSM97962,GSM97964,GSM97970
Medulloblastoma MDL 
Meningioma MNG
Oligodendroglioma OLG
Supplementary Table 2.  (Continued) GEO microarray sample IDs used in this study. 
 
 
 
 	  
GSE 12907
GSM322969,GSM323054,GSM323523,GSM323524,GSM323525,GS
M323526,GSM323527,GSM323528,GSM323529,GSM323530,GSM3
23531,GSM323554,GSM323555,GSM323557,GSM323558,GSM3235
59,GSM323560,GSM323561,GSM323562,GSM323563,GSM323564
GSE 5675
GSM132714,GSM132715,GSM132716,GSM132717,GSM132718,GS
M132719,GSM132720,GSM132722,GSM132723,GSM132728,GSM1
32729,GSM132730 ,GSM132733,GSM132736,GSM132738 
,GSM132741 ,GSM132744,GSM132747,GSM132748,GSM132750 
,GSM132751,GSM132752,GSM132753,GSM132754,GSM132759,GS
M132761,GSM132763,GSM132765,GSM132768,GSM132769,GSM1
32770,GSM132771,GSM132772,GSM132773,GSM132774,GSM1327
75,GSM132776,GSM132777,GSM132778,GSM132779,GSM132780
GSE 3526
GSM80565,GSM80566,GSM80567,GSM80568,GSM80569,GSM8057
0,GSM80571,GSM80572,GSM80573,GSM80574,GSM80575,GSM80
581,GSM80585,GSM80586,GSM80587,GSM80591,GSM80592,GSM
80593,GSM80594,GSM80595,GSM80596,GSM80597,GSM80598,GS
M80599,GSM80600,GSM80601,GSM80616,GSM80617,GSM80618,
GSM80619,GSM80620,GSM80621,GSM80622,GSM80623,GSM8062
6,GSM80627,GSM80628,GSM80636,GSM80637,GSM80638,GSM80
639,GSM80640,GSM80641,GSM80642,GSM80643,GSM80644,GSM
80645,GSM80646,GSM80647,GSM80650,GSM80651,GSM80652,GS
M80653,GSM80660,GSM80661,GSM80662,GSM80663,GSM80664,
GSM80665,GSM80666,GSM80667,GSM80668,GSM80669,GSM8067
0,GSM80671,GSM80675,GSM80676,GSM80677,GSM80678,GSM80
679,GSM80680,GSM80681,GSM80682,GSM80683,GSM80684,GSM
80690,GSM80691,GSM80692,GSM80693,GSM80699,GSM80700,GS
M80701,GSM80702,GSM80703,GSM80704,GSM80705,GSM80706,
GSM80708,GSM80709,GSM80711,GSM80713,GSM80714,GSM8071
5,GSM80721,GSM80722,GSM80723,GSM80724,GSM80744,GSM80
745,GSM80746,GSM80747,GSM80752,GSM80754,GSM80756,GSM
80760,GSM80761,GSM80762,GSM80763,GSM80766,GSM80767,GS
M80772,GSM80773,GSM80774,GSM80775,GSM80800,GSM80801,
GSM80802,GSM80803,GSM80804,GSM80817,GSM80818,GSM8081
9,GSM80830,GSM80831,GSM80832,GSM80833,GSM80834,GSM80
835,GSM80836,GSM80837,GSM80838,GSM80839,GSM80840,GSM
80841,GSM80847,GSM80848,GSM80849,GSM80851,GSM80852,GS
M80855,GSM80858,GSM80859,GSM80860,GSM80861,GSM80862,
GSM80863
GSE 7307
GSM175842,GSM175843,GSM175844,GSM175845,GSM175849,GS
M175850,GSM175851,GSM176153,GSM175852,GSM175853,GSM1
75854,GSM176048,GSM175855,GSM175856,GSM175857,GSM1758
58,GSM175846,GSM175847,GSM175848,GSM176150,GSM175871,
GSM175872,GSM175873,GSM176059,GSM175874,GSM175875,GS
M175876,GSM175877,GSM176215,GSM175901,GSM175902,GSM1
75903,GSM175904,GSM175987,GSM175988,GSM176174,GSM1761
75,GSM175989,GSM175990,GSM176170,GSM176171,GSM176172,
GSM176173,GSM176178,GSM176179,GSM176180,GSM176181,GS
M176182,GSM176183,GSM176184,GSM176185,GSM176161,GSM1
76162,GSM176163,GSM176164,GSM176056,GSM176073
Normal Brain normal
PAPilocyticAstrocytoma
Table S3.  Node marker panel for brain cancer and normal transcriptome classification. 	  
	  
 
 
 
  Gene symbol Gene name Chomosomelocus
Affymetrix
Probe ID Gene symbol Gene name
Chomosome
locus
Affymetrix
Probe ID
 EPN  GBM  MDL  
 MNG  OLG  PA
3  normal   PURA Purine-rich element binding protein A 5q31 204021_s_at PRPF40A PRP40 pre-mRNA processing factor 40 homolog A  (S. cerevisiae) 2q23.3 218053_at 1
 EPN  GBM  MDL
  NRCAM Neuronal cell adhesion molecule 7q31 204105_s_at ISLR Immunoglobulin superfamily containing leucine-rich repeat 15q23-q24 207191_s_at
 OLG  PA
  IDH2 Isocitrate dehydrogenase 2 (NADP+), mitochondrial 15q26.1 210046_s_at GMDS GDP-mannose 4,6-dehydratase 6p25 214106_s_at
5  MNG   ISLR Immunoglobulin superfamily containing leucine-rich repeat 15q23-q24 207191_s_at NRCAM Neuronal cell adhesion molecule 7q31 204105_s_at 1
  SALL1 Sal-like 1 (Drosophila) 16q12.1 206893_at PAFAH1B3 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 19q13.1 203228_at
  SRI Sorcin 7q21 208920_at NBEA Neurobeachin 13q13 221207_s_at
  DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 210749_x_at TIA1 TIA1 cytotoxic granule-associated RNA binding protein 2p13 201447_at
  DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 208779_x_at MAB21L1 Mab-21-like 1 (C. elegans) 13q13 206163_at
  ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 1q42.13 203723_at PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae 13q12.3 204742_s_at
  PAFAH1B3 Platelet-activating factor acetylhydrolase 1b, catalytic subunit 3 19q13.1 203228_at SALL1 Sal-like 1 (Drosophila) 16q12.1 206893_at
  NBEA Neurobeachin 13q13 221207_s_at SRI Sorcin 7q21 208920_at
  TIA1 TIA1 cytotoxic granule-associated RNA binding protein 2p13 201447_at DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 210749_x_at
  MAB21L1 Mab-21-like 1 (C. elegans) 13q13 206163_at DDR1 Discoidin domain receptor tyrosine kinase 1 6p21.3 208779_x_at
  PDS5B PDS5, regulator of cohesion maintenance, homolog B (S. cerevisiae 13q12.3 204742_s_at ITPKB Inositol 1,4,5-trisphosphate 3-kinase B 1q42.13 203723_at
  NUP62CL Nucleoporin 62kDa C-terminal like Xq22.3 220520_s_at ZNF280A Zinc finger protein 280A 22q11.22 216034_at
  GALNS Galactosamine (N-acetyl)-6-sulfate sulfatase 16q24.3 206335_at WAS Wiskott-Aldrich syndrome (eczema-thrombocytopenia) Xp11.4-p11.21 38964_r_at
  CELSR1 Cadherin, EGF LAG seven-pass G-type receptor 1 (flamingo homolog, Drosophila) 22q13.3 41660_at OR10H3
Olfactory receptor, family 10, subfamily H, 
member 3 19p13.1 208520_at
  TLE4 Transducin-like enhancer of split 4 (E(sp1) homolog, Drosophila) 9q21.31 216997_x_at OLIG2 Oligodendrocyte lineage transcription factor 2 21q22.11 213824_at
8
Node #
2
4
6
7
k
 EPN  GBM
 OLG  PA
 MDL
 EPN
Purine-rich element binding protein A 5q31 204021_s_at  PRPF40A PRP40 pre-mRNA processing factor 40 homolog A  (S. cerevisiae) 2q23.3 218053_at      PURA
Gene i
2
1
Gene j
4
2
1
  Node phenotype 
  classes
Table S3.  (Continued) Node marker panel for brain cancer and normal transcriptome classification. 
 
 	  
Node #: Corresponds to numerical labels shown in the brain phenotype diagnostic hierarchy (Fig. 1).  Brain phenotype abbreviation (name): EPN (Ependymoma), GBM 
(Glioblastoma multiforme), MDL (Medulloblastoma), MNG (Meningioma), normal (Normal brain), OLG (Oligodendroglioma), and PA (Pilocytic astrocytoma).  Gene i / Gene j: 
the gene expressed higher and lower in the gene-pair, respectively, within each corresponding phenotype.  Gene name / Chromosome locus: according to Entrez Gene.  
Affymetrix Probe ID: For both Affymetrix Human Genome U133A and U133Plus2.0 Arrays.  k: The minimum number of gene-pair classifiers whose decision rule outcomes for 
a test sample are required to be ‘true (= 1)’ for the sample to be classified as the phenotype(s) of the corresponding node.  
Gene symbol Gene name Chomosomelocus
Affymetrix
Probe ID Gene symbol Gene name
Chomosome
locus
Affymetrix
Probe ID
Node # k
Gene i Gene j
  Node phenotype 
  classes
9  GBM  OLG  PA   ZNF280A Zinc finger protein 280A 22q11.22 216034_at NUP62CL Nucleoporin 62kDa C-terminal like Xq22.3 220520_s_at 1
  DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at KCNMA1
Potassium large conductance calcium-
activated channel, subfamily M, alpha member 
1
10q22.3 221584_s_at
  COX7A2 Cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 6q12 217249_x_at GNPTAB
N-acetylglucosamine-1-phosphate transferase, 
alpha and beta subunits 12q23.2 212959_s_at
  KCNMA1 Potassium large conductance calcium-activated 
channel, subfamily M, alpha member 1
10q22.3 221584_s_at DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at
  GNPTAB N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12q23.2 212959_s_at NDUFS2
NADH dehydrogenase (ubiquinone) Fe-S 
protein 2, 49kDa (NADH-coenzyme Q 
reductase)
1q23 201966_at
  APOD Apolipoprotein D 3q26.2-qter 201525_at PPIA Peptidylprolyl isomerase A (cyclophilin A) 7p13 211378_x_at
  CD59 CD59 molecule, complement regulatory protein 11p13 212463_at SNRPB2 Small nuclear ribonucleoprotein polypeptide B 20p12.1 202505_at
  SEMA3E Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3E 7q21.11 206941_x_at ADAMTS3
ADAM metallopeptidase with thrombospondin 
type 1 motif, 3 4q13.3 214913_at
  CD59 CD59 molecule, complement regulatory protein 11p13 200985_s_at HINT1 Histidine triad nucleotide binding protein 1 5q31.2 208826_x_at
  BAMBI BMP and activin membrane-bound inhibitor homolog (Xenopus laevis) 10p12.13-p11.2 203304_at CIAPIN1 Cytokine induced apoptosis inhibitor 1 16q13-q21 208968_s_at
  FLNA Filamin A, alpha Xq28 214752_x_at TNKS2 Tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 10q23.3 218228_s_at
  ITGB3BP Integrin beta 3 binding protein (beta3-endonexin) 1p31.3 205176_s_at RB1CC1 RB1-inducible coiled-coil 1 8q11 202034_x_at
  DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13.13 215693_x_at TRIM8 Tripartite motif-containing 8 10q24.3 221012_s_at
13  OLG   LARP5 La ribonucleoprotein domain family, member 4B 10p15.3 208953_at ANXA1 Annexin A1 9q12-q21.2 201012_at 1
10
11
12
 GBM  OLG
 PA
 GBM 1
3
1
Table S4.  Decision-tree marker panel for brain cancer and normal transcriptome classification. 
 
	  	  
For each classifier decision rule (i.e. Is Gene i > Gene j ?), 1 and 0 delineates ‘true’ and ‘false’, respectively, and ‘ – ’ 
denotes that the outcome is not used for classification.  The vertical binary pattern under each class label corresponds to 
a phenotype-specific molecular signature.  	  
Gene symbol AffymetrixProbe ID Gene symbol
Affymetrix
Probe ID EPN GBM MDL MNG OLG PA normal
PRPF40A 218053_at PURA 204021_s_at 1 1 1 1 1 1 0
NRCAM 204105_s_at ISLR 207191_s_at 1 1 1 0 1 1 -
SRI 208920_at NBEA 221207_s_at 1 1 0 - 1 1 -
NUP62CL 220520_s_at OR10H3 208520_at 1 0 - - 0 0 -
DDX27 215693_x_at KCNMA1 221584_s_at - 1 - - 1 0 -
FLNA 214752_x_at TNKS2 218228_s_at - 1 - - 0 - -
Gene i Gene j Brain phenotype binary signature
Table S5.  Summary of expression differences between genes-pair classifiers. 
 
 
 
Node #: Corresponds to numerical labels shown in the brain phenotype diagnostic hierarchy (Fig. 1).  Brain 
phenotype abbreviation (name): EPN (Ependymoma), GBM (Glioblastoma multiforme), MDL (Medulloblastoma), 
MNG (Meningioma), normal (Normal brain), OLG (Oligodendroglioma), and PA (Pilocytic astrocytoma).  Sample 
number: Number of total samples in classes of respective Node #.  Gene i / Gene j: the gene expressed higher and 
lower in the gene-pair, respectively, within each corresponding phenotype.  Gene name / Chromosome locus: 
according to Entrez Gene.  Affymetrix Probe ID: For both Affymetrix Human Genome U133A and U133Plus2.0 
Arrays.  k: The minimum number of gene-pair classifiers whose decision rule outcomes for a test sample are required 
to be ‘true (= 1)’ for the sample to be classified as the phenotype(s) of the corresponding node.  Ranked expression 
differences of each gene pair (i.e. Rank_gene_i – Rank_gene_j) were calculated for each sample, and Mean, St. dev., 
Max., Min., and Median were found across all samples within classes of respective Node #. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Gene symbol AffymetrixProbe ID Gene symbol
Affymetrix
Probe ID
 EPN  GBM  MDL  
 MNG  OLG  PA
3  normal 203   PURA 204021_s_at PRPF40A 218053_at 1 1,793.5 1,122.2 9,249.0 176.0 1,591.0
 EPN  GBM  MDL
  NRCAM 204105_s_at ISLR 207191_s_at 10,376.0 2,475.5 13,271.0 -7,491.0 11,283.0
 OLG  PA
  IDH2 210046_s_at GMDS 214106_s_at 5,153.1 1,647.1 9,264.0 -6,662.0 5,238.0
5  MNG 161   ISLR 207191_s_at NRCAM 204105_s_at 1 8,568.9 2,449.9 11,884.0 -11,674.0 8,977.0
  SALL1 206893_at PAFAH1B3 203228_at 8,239.6 2,767.1 12,574.0 -9,364.0 8,728.0
  SRI 208920_at NBEA 221207_s_at 4,513.8 2,001.8 10,692.0 -401.0 4,536.5
  DDR1 210749_x_at TIA1 201447_at 4,227.7 1,528.7 9,580.0 -3,227.0 4,536.0
  DDR1 208779_x_at MAB21L1 206163_at 9,514.9 2,223.0 13,251.0 -1,759.0 10,267.0
  ITPKB 203723_at PDS5B 204742_s_at 7,051.7 2,551.4 11,373.0 -1,524.0 7,478.5
  PAFAH1B3 203228_at SALL1 206893_at 8,729.6 2,776.6 12,096.0 9.0 9,341.0
  NBEA 221207_s_at SRI 208920_at 3,858.3 2,074.7 8,440.0 -28.0 3,715.0
  TIA1 201447_at DDR1 210749_x_at 3,476.4 1,618.5 8,709.0 27.0 3,481.0
  MAB21L1 206163_at DDR1 208779_x_at 4,510.6 1,845.9 8,771.0 -5,415.0 4,562.0
  PDS5B 204742_s_at ITPKB 203723_at 5,495.4 2,515.1 11,625.0 -2,026.0 5,538.0
  NUP62CL 220520_s_at ZNF280A 216034_at 5,676.0 3,444.6 11,512.0 -830.0 6,079.5
  GALNS 206335_at WAS 38964_r_at 3,952.7 2,095.5 7,831.0 -1,216.0 4,098.5
  CELSR1 41660_at OR10H3 208520_at 4,959.8 2,798.6 11,365.0 -1,367.0 5,058.5
  TLE4 216997_x_at OLIG2 213824_at 3,423.4 2,401.5 9,765.0 -3,239.0 3,386.5
2
4
2
MedianMin.Max.St. dev.Mean
4,370.5-2,593.010,889.01,685.5
k
1
1557
718
Sample 
number
8  EPN
101
102
4
6  EPN  GBM OLG  PA
7  MDL
456
4,314.72   PRPF40A 218053_at      PURA 204021_s_at
Node #   Node phenotype   classes
Gene i Gene j
Table S5.  (Continued) Summary of expression differences between genes-pair classifiers. 
 
 
 
Node #: Corresponds to numerical labels shown in the brain phenotype diagnostic hierarchy (Fig. 1).  Brain 
phenotype abbreviation (name): EPN (Ependymoma), GBM (Glioblastoma multiforme), MDL (Medulloblastoma), 
MNG (Meningioma), normal (Normal brain), OLG (Oligodendroglioma), and PA (Pilocytic astrocytoma).  Sample 
number: Number of total samples in classes of respective Node #.  Gene i / Gene j: the gene expressed higher and 
lower in the gene-pair, respectively, within each corresponding phenotype.  Gene name / Chromosome locus: 
according to Entrez Gene.  Affymetrix Probe ID: For both Affymetrix Human Genome U133A and U133Plus2.0 
Arrays.  k: The minimum number of gene-pair classifiers whose decision rule outcomes for a test sample are required 
to be ‘true (= 1)’ for the sample to be classified as the phenotype(s) of the corresponding node.  Ranked expression 
differences of each gene pair (i.e. Rank_gene_i – Rank_gene_j) were calculated for each sample, and Mean, St. dev., 
Max., Min., and Median were found across all samples within classes of respective Node #. 
 	  
  Gene symbol AffymetrixProbe ID Gene symbol
Affymetrix
Probe ID
MedianMin.Max.St. dev.MeankSample numberNode #
  Node phenotype 
  classes
Gene i Gene j
9  GBM  OLG  PA 354   ZNF280A 216034_at NUP62CL 220520_s_at 1 1,392.5 673.9 3,211.0 -4,279.0 1,354.0
  DDX27 215693_x_at KCNMA1 221584_s_at 2,144.8 1,366.3 6,451.0 -1,681.0 2,124.5
  COX7A2 217249_x_at GNPTAB 212959_s_at 1,777.2 1,106.8 5,125.0 -2,040.0 1,664.0
  KCNMA1 221584_s_at DDX27 215693_x_at 1,832.2 942.5 3,558.0 105.0 1,853.0
  GNPTAB 212959_s_at NDUFS2 201966_at 1,149.7 737.3 3,061.0 -825.0 1,112.5
  APOD 201525_at PPIA 211378_x_at 121.4 117.3 494.0 -426.0 104.5
  CD59 212463_at SNRPB2 202505_at 1,169.1 1,038.0 3,989.0 -2,247.0 1,059.0
  SEMA3E 206941_x_at ADAMTS3 214913_at 4,376.3 3,026.1 8,551.0 -8,061.0 5,194.5
  CD59 200985_s_at HINT1 208826_x_at 388.5 422.5 1,586.0 -270.0 214.5
  BAMBI 203304_at CIAPIN1 208968_s_at 1,976.4 975.1 3,802.0 -594.0 1,984.0
  FLNA 214752_x_at TNKS2 218228_s_at 3,238.8 2,804.3 9,691.0 -4,133.0 3,557.0
  ITGB3BP 205176_s_at RB1CC1 202034_x_at 1,793.7 2,357.9 8,665.0 -4,597.0 1,560.0
  DDX27 215693_x_at TRIM8 221012_s_at 1,819.1 1,492.6 6,083.0 -1,099.0 1,636.0
13  OLG 61   LARP5 208953_at ANXA1 201012_at 1 2,843.4 3,463.0 9,055.0 -5,831.0 2,788.0
1
3
1
11  PA
12  GBM
10  GBM  OLG 292
62
231
Table S6.  Hold-one-lab-in validation accuracies of glioblastoma signatures. 
 
 
 
 
 
 
 
 
 
 
 
GBM training set (sample size) GBM test set (sample size)
UC EPN GBM MDL MNG OLG PA Total
GSE4271 (76) 2.63% 57.89% 9.21% 17.11% 5.26% 1.32% 6.58% 76
2 44 7 13 4 1 5 76
GBM MNG Total
GSE8692 (6) 83.33% 16.67% 6
5 1 6  
EPN GBM MNG Total
GSE9171 (13) 92.31% 0.00% 7.69% 13
12 0 1 13
EPN GBM MDL MNG PA Total
GSE4290 (77) 85.71% 0.00% 2.60% 5.19% 6.49% 77
66 0 2 4 5 77
UC GBM PA normal Total
GSE4412 (59) 11.86% 77.97% 8.47% 1.69% 59
7 46 5 1 59
GBM Total
GSE8692 (6) 100.0% 6
6 6
GBM 6 Total
GSE9171 (13) 92.31% 7.69% 13
12 1 13
UC GBM MNG PA Total
GSE4290 (77) 5.19% 77.92% 1.30% 15.58% 77
4 60 1 12 77
UC EPN GBM MDL MNG PA normal Total
GSE4412 (59) 5.08% 13.56% 47.46% 1.69% 3.39% 27.12% 1.69% 59
3 8 28 1 2 16 1 59
UC EPN GBM MDL PA normal Total
GSE4271 (76) 9.21% 32.89% 18.42% 5.26% 32.89% 1.32% 76
7 25 14 4 25 1 76
EPN GBM MDL PA Total
GSE9171 (13) 61.54% 15.38% 15.38% 7.69% 13
8 2 2 1 13
UC EPN GBM MDL MNG PA normal Total
GSE4290 (77) 14.29% 42.86% 7.79% 1.30% 1.30% 25.97% 6.49% 77
11 33 6 1 1 20 5 77
Predicted phenotype / % of test set / samples of test set
GSE4412 (59)
GSE4271 (76)
GSE8692 (6)
Table S6.  (Continued) Hold-one-lab-in validation accuracies of glioblastoma signatures. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
UC EPN GBM MDL MNG PA Total
GSE4412 (59) 35.59% 13.56% 0.00% 1.69% 5.08% 44.07% 59
21 8 0 1 3 26 59
UC EPN GBM MDL MNG PA Total
GSE4271 (76) 19.74% 38.16% 0.00% 6.58% 3.95% 31.58% 76
15 29 0 5 3 24 76
UC GBM MNG PA Total
GSE8692 (6) 66.67% 0.00% 16.67% 16.67% 6
4 0 1 1 6
UC EPN GBM MDL PA normal Total
GSE4290 (77) 10.39% 40.26% 0.00% 1.30% 46.75% 1.30% 77
8 31 0 1 36 1 77
UC GBM NB PA normal Total
GSE4412 (59) 5.08% 52.54% 27.12% 13.56% 1.69% 59
3 31 16 8 1 59
UC EPN GBM MDL OLG PA Total
GSE4271 (76) 1.32% 1.32% 60.53% 3.95% 15.79% 17.11% 76
1 1 46 3 12 13 76
UC GBM NB PA Total
GSE8692 (6) 33.33% 16.67% 16.67% 33.33% 6
2 1 1 2 6
UC GBM Total
GSE9171 (13) 7.69% 92.31% 13
1 12 13
GSE4290 (77)
GSE9171 (13)
Table S7.  Hold-one-lab-in (H1LI) and leave-one-lab-out (L1LO) validation accuracies of 
glioblastoma signatures when training data were constrained to 50 total samples.  
 
 
 
H1LI and L1LO validations were performed ten times for each category of training data.  In each validation trial, 50 
samples were randomly selected from the single microarray dataset (for H1L1) or from the multi-study, combined 
dataset (for L1LO).   	  
GBM prediction 
Average accuracy St. dev.
  GSE4271 40.26% 14.98%
  GSE8692 96.67% 7.03%
  GSE9171 6.15% 3.24%
  GSE4290 2.47% 2.10%
  GSE4412 58.98% 21.64%
  GSE8692 74.00% 11.43%
  GSE9171 73.08% 10.41%
  GSE4290 49.48% 26.56%
  GSE4412 38.47% 10.23%
  GSE4271 43.13% 16.12%
  GSE8692 23.33% 9.08%
  GSE9171 57.70% 16.79%
GSE4271, GSE8692, 
GSE9171, GSE4290   GSE4412 82.20% 10.39%
GSE4412, GSE8692, 
GSE9171, GSE4290   GSE4271 54.87% 7.18%
GSE4412, GSE4271, 
GSE8692, GSE9171   GSE4290 72.08% 15.29%
L1LO
GSE4412
GSE4271
GSE4290
36.39%
63.89%
40.66%
69.72%
GBM training set
(50 samples)   GBM test setMethod
H1LI
Average
performance
Table S8.  Ten-fold cross-validation accuracies when only the node marker panel was required to 
reach unique diagnoses. 
 
 
 
Sample size: Average proportion of total samples that reached unique diagnoses via node marker panel.  Accuracy: 
Reflects average performance in ten-fold cross-validation conducted ten times.   	  	  
  Phenotype Total samples Sample size (%) Accuracy (%)
  EPN 102 93.1 95.8
  GBM 231 88.9 92.7
  MDL 101 95.0 95.8
  MNG 161 98.8 97.5
  OLG 61 77.0 74.5
  PA 62 90.3 96.4
  Normal 203 97.9 99.5
  Average - 91.6 93.2
Table S9.  Functional roles of 11 previously identified GBM serum markers that are present in 
our extracellular-product encoding marker-panel. 
 
 
 
ahttp://www.ncbi.nlm.nih.gov/gene 
 	  
Gene Gene name Functional rolea
APOD Apolipoprotein D
This gene encodes a component of high density lipoprotein that has no marked similarity to other apolipoprotein 
sequences. It has a high degree of homology to plasma retinol-binding protein and other members of the alpha 2 
microglobulin protein superfamily of carrier proteins, also known as lipocalins. This glycoprotein is closely 
associated with the enzyme lecithin:cholesterol acyltransferase - an enzyme involved in lipoprotein metabolism.
CALU Calumenin
The product of this gene is a calcium-binding protein localized in the endoplasmic reticulum (ER) and it is 
involved in such ER functions as protein folding and sorting. This protein belongs to a family of multiple EF-hand 
proteins (CERC) that include reticulocalbin, ERC-55, and Cab45 and the product of this gene. Alternatively 
spliced transcript variants encoding different isoforms have been identified. 
CD163 Cluster of Differentiation 163
The protein encoded by this gene is a member of the scavenger receptor cysteine-rich (SRCR) superfamily, and 
is exclusively expressed in monocytes and macrophages. It functions as an acute phase-regulated receptor 
involved in the clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages, and may 
thereby protect tissues from free hemoglobin-mediated oxidative damage. This protein may also function as an 
innate immune sensor for bacteria and inducer of local inflammation. Alternatively spliced transcript variants 
encoding different isoforms have been described for this gene.
CHI3L1 Chitinase-3-like protein 1 
Chitinases catalyze the hydrolysis of chitin, which is an abundant glycopolymer found in insect exoskeletons and 
fungal cell walls. The glycoside hydrolase 18 family of chitinases includes eight human family members. This 
gene encodes a glycoprotein member of the glycosyl hydrolase 18 family. The protein lacks chitinase activity and 
is secreted by activated macrophages, chondrocytes, neutrophils and synovial cells. The protein is thought to 
play a role in the process of inflammation and tissue remodeling.
CSF1 Colony stimulating factor 1
The protein encoded by this gene is a cytokine that controls the production, differentiation, and function of 
macrophages. The active form of the protein is found extracellularly as a disulfide-linked homodimer, and is 
thought to be produced by proteolytic cleavage of membrane-bound precursors. The encoded protein may be 
involved in development of the placenta. Alternate splicing results in multiple transcript variants. 
EGFR Epidermal growth factor receptor
The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase 
superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface 
protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and 
tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung 
cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for 
this gene.
IGFBP2 Insulin-like growth factor binding protein 2
Inhibits IGF-mediated growth and developmental rates. IGF-binding proteins prolong the half-life of the IGFs and 
have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter 
the interaction of IGFs with their cell surface receptors.
NID1 Nidogen 1
This gene encodes a member of the nidogen family of basement membrane glycoproteins. The protein interacts 
with several other components of basement membranes, and may play a role in cell interactions with the 
extracellular matrix.
PDGFC Platelet derived growth factor C
The protein encoded by this gene is a member of the platelet-derived growth factor family. The four members of 
this family are mitogenic factors for cells of mesenchymal origin and are characterized by a core motif of eight 
cysteines. This gene product appears to form only homodimers. It differs from the platelet-derived growth factor 
alpha and beta polypeptides in having an unusual N-terminal domain, the CUB domain. Alternatively spliced 
transcript variants have been found for this gene.
PSG9 Pregnancy specific beta-1-glycoprotein 9
The human pregnancy-specific glycoproteins (PSGs) are a group of molecules that are mainly produced by the 
placental syncytiotrophoblasts during pregnancy. PSGs comprise a subgroup of the carcinoembryonic antigen 
(CEA) family, which belongs to the immunoglobulin superfamily.
PTN Pleiotrophin
Secreted growth factor that induces neurite outgrowth and which is mitogenic for fibroblasts, epithelial, and 
endothelial cells. Binds anaplastic lymphoma kinase (ALK) which induces MAPK pathway activation, an important 
step in the anti-apoptotic signaling of PTN and regulation of cell proliferation
Table S10.  Ten-fold cross-validation accuracies of gene-pair classifiers composed of genes that 
encode extracellular products. 
 
 
 
aAccuracies reflect average performance in ten-fold cross-validation conducted ten times.  The main diagonal gives the 
average classification accuracy of each class (bold), and the off-diagonal elements show the erroneous predictions.  
bUC (Unclassified samples). When using the node classifiers, expression profiles that did not exert a signature of any 
phenotype (i.e., did not percolate down to at least one positive terminal node) were rejected from classification.  In this 
case, the Unclassified sample is treated as a misclassification. 	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